WO2010064633A1 - チアゾール環を含むカルボン酸誘導体およびその医薬用途 - Google Patents
チアゾール環を含むカルボン酸誘導体およびその医薬用途 Download PDFInfo
- Publication number
- WO2010064633A1 WO2010064633A1 PCT/JP2009/070185 JP2009070185W WO2010064633A1 WO 2010064633 A1 WO2010064633 A1 WO 2010064633A1 JP 2009070185 W JP2009070185 W JP 2009070185W WO 2010064633 A1 WO2010064633 A1 WO 2010064633A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- group
- alkyl group
- substituent
- compound
- aryl
- Prior art date
Links
- 150000001732 carboxylic acid derivatives Chemical class 0.000 title claims description 39
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical group C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 title description 4
- 125000000217 alkyl group Chemical group 0.000 claims abstract description 116
- -1 hydroxymethylene group Chemical group 0.000 claims abstract description 86
- 125000003118 aryl group Chemical group 0.000 claims abstract description 71
- 125000001072 heteroaryl group Chemical group 0.000 claims abstract description 51
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims abstract description 51
- 150000003839 salts Chemical class 0.000 claims abstract description 44
- 125000005843 halogen group Chemical group 0.000 claims abstract description 35
- 208000031226 Hyperlipidaemia Diseases 0.000 claims abstract description 32
- 239000003814 drug Substances 0.000 claims abstract description 26
- 125000004430 oxygen atom Chemical group O* 0.000 claims abstract description 17
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims abstract description 12
- 229910052717 sulfur Inorganic materials 0.000 claims abstract description 10
- 125000004434 sulfur atom Chemical group 0.000 claims abstract description 9
- 125000001424 substituent group Chemical group 0.000 claims description 113
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 41
- 206010012601 diabetes mellitus Diseases 0.000 claims description 32
- 238000004519 manufacturing process Methods 0.000 claims description 32
- 238000000034 method Methods 0.000 claims description 31
- 125000005915 C6-C14 aryl group Chemical group 0.000 claims description 29
- 239000012453 solvate Substances 0.000 claims description 24
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 18
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 claims description 17
- 239000002253 acid Substances 0.000 claims description 17
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 13
- 201000010099 disease Diseases 0.000 claims description 11
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 11
- 125000000446 sulfanediyl group Chemical group *S* 0.000 claims description 11
- 208000011775 arteriosclerosis disease Diseases 0.000 claims description 10
- 206010003210 Arteriosclerosis Diseases 0.000 claims description 9
- 208000031225 myocardial ischemia Diseases 0.000 claims description 9
- 229910052799 carbon Inorganic materials 0.000 claims description 8
- HJOIZSBXLWMMBN-GOSISDBHSA-N 2-[[4-[(1s)-2-[4-(4-fluorophenyl)phenoxy]-1-hydroxyethyl]-1,3-thiazol-2-yl]sulfanyl]-2-methylpropanoic acid Chemical compound S1C(SC(C)(C)C(O)=O)=NC([C@H](O)COC=2C=CC(=CC=2)C=2C=CC(F)=CC=2)=C1 HJOIZSBXLWMMBN-GOSISDBHSA-N 0.000 claims description 6
- 230000002265 prevention Effects 0.000 claims description 6
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 5
- 125000005160 aryl oxy alkyl group Chemical group 0.000 claims description 5
- 125000004446 heteroarylalkyl group Chemical group 0.000 claims description 5
- 230000000069 prophylactic effect Effects 0.000 claims description 5
- HJOIZSBXLWMMBN-SFHVURJKSA-N 2-[[4-[(1r)-2-[4-(4-fluorophenyl)phenoxy]-1-hydroxyethyl]-1,3-thiazol-2-yl]sulfanyl]-2-methylpropanoic acid Chemical compound S1C(SC(C)(C)C(O)=O)=NC([C@@H](O)COC=2C=CC(=CC=2)C=2C=CC(F)=CC=2)=C1 HJOIZSBXLWMMBN-SFHVURJKSA-N 0.000 claims description 4
- HJOIZSBXLWMMBN-UHFFFAOYSA-N 2-[[4-[2-[4-(4-fluorophenyl)phenoxy]-1-hydroxyethyl]-1,3-thiazol-2-yl]sulfanyl]-2-methylpropanoic acid Chemical compound S1C(SC(C)(C)C(O)=O)=NC(C(O)COC=2C=CC(=CC=2)C=2C=CC(F)=CC=2)=C1 HJOIZSBXLWMMBN-UHFFFAOYSA-N 0.000 claims description 4
- 125000005018 aryl alkenyl group Chemical group 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 4
- 229940126585 therapeutic drug Drugs 0.000 claims description 4
- CWIDMGIUHZHDBT-UHFFFAOYSA-N 2-[[4-[2-[4-(4-chlorophenyl)phenoxy]-1-hydroxyethyl]-1,3-thiazol-2-yl]sulfanyl]-2-methylpropanoic acid Chemical compound S1C(SC(C)(C)C(O)=O)=NC(C(O)COC=2C=CC(=CC=2)C=2C=CC(Cl)=CC=2)=C1 CWIDMGIUHZHDBT-UHFFFAOYSA-N 0.000 claims description 3
- DTDIRQHNQJNAHO-UHFFFAOYSA-N 2-[[4-[2-[4-(4-chlorophenyl)phenoxy]acetyl]-1,3-thiazol-2-yl]sulfanyl]-2-methylpropanoic acid Chemical compound S1C(SC(C)(C)C(O)=O)=NC(C(=O)COC=2C=CC(=CC=2)C=2C=CC(Cl)=CC=2)=C1 DTDIRQHNQJNAHO-UHFFFAOYSA-N 0.000 claims description 3
- JGXRFQRZSGLVLY-UHFFFAOYSA-N 2-[[4-[2-[4-(4-fluorophenyl)phenoxy]-1-methoxyethyl]-1,3-thiazol-2-yl]sulfanyl]-2-methylpropanoic acid Chemical compound C=1SC(SC(C)(C)C(O)=O)=NC=1C(OC)COC(C=C1)=CC=C1C1=CC=C(F)C=C1 JGXRFQRZSGLVLY-UHFFFAOYSA-N 0.000 claims description 3
- ABBBIQCZPQNDAD-UHFFFAOYSA-N 2-[[4-[2-[4-(4-fluorophenyl)phenoxy]acetyl]-1,3-thiazol-2-yl]sulfanyl]-2-methylpropanoic acid Chemical compound S1C(SC(C)(C)C(O)=O)=NC(C(=O)COC=2C=CC(=CC=2)C=2C=CC(F)=CC=2)=C1 ABBBIQCZPQNDAD-UHFFFAOYSA-N 0.000 claims description 3
- 239000004480 active ingredient Substances 0.000 claims description 3
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- 229940043274 prophylactic drug Drugs 0.000 claims description 2
- 150000001875 compounds Chemical class 0.000 abstract description 192
- 230000009471 action Effects 0.000 abstract description 17
- 102000023984 PPAR alpha Human genes 0.000 abstract description 13
- 108091008725 peroxisome proliferator-activated receptors alpha Proteins 0.000 abstract description 13
- 229940124597 therapeutic agent Drugs 0.000 abstract description 8
- 230000003449 preventive effect Effects 0.000 abstract description 6
- 239000000556 agonist Substances 0.000 abstract description 4
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 120
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 102
- 239000002904 solvent Substances 0.000 description 68
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 50
- 238000006243 chemical reaction Methods 0.000 description 48
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 40
- 239000000243 solution Substances 0.000 description 40
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 30
- 239000000203 mixture Substances 0.000 description 29
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 25
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 24
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 24
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 24
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 21
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 21
- 239000002585 base Substances 0.000 description 21
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 20
- 210000004369 blood Anatomy 0.000 description 20
- 239000008280 blood Substances 0.000 description 20
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 20
- 239000012156 elution solvent Substances 0.000 description 19
- 238000005160 1H NMR spectroscopy Methods 0.000 description 18
- 230000002411 adverse Effects 0.000 description 18
- 125000003545 alkoxy group Chemical group 0.000 description 18
- 238000004440 column chromatography Methods 0.000 description 18
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 17
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 16
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 16
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 16
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 16
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 16
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 15
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 15
- 229910052739 hydrogen Inorganic materials 0.000 description 15
- 229920006395 saturated elastomer Polymers 0.000 description 14
- 125000004432 carbon atom Chemical group C* 0.000 description 13
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 11
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 11
- 239000013078 crystal Substances 0.000 description 11
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 10
- 239000007787 solid Substances 0.000 description 10
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 10
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 9
- 239000003054 catalyst Substances 0.000 description 9
- 229940079593 drug Drugs 0.000 description 9
- 229910052751 metal Inorganic materials 0.000 description 9
- 239000002184 metal Substances 0.000 description 9
- 238000012360 testing method Methods 0.000 description 9
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 8
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 8
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 8
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 8
- 125000004093 cyano group Chemical group *C#N 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 150000002170 ethers Chemical class 0.000 description 8
- 239000012046 mixed solvent Substances 0.000 description 8
- 125000000449 nitro group Chemical class [O-][N+](*)=O 0.000 description 8
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 8
- 239000011780 sodium chloride Substances 0.000 description 8
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical class O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 8
- 229940126062 Compound A Drugs 0.000 description 7
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 description 7
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 7
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 7
- 230000003287 optical effect Effects 0.000 description 7
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 7
- 235000017557 sodium bicarbonate Nutrition 0.000 description 7
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 6
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical group [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 6
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 6
- 102000003728 Peroxisome Proliferator-Activated Receptors Human genes 0.000 description 6
- 108090000029 Peroxisome Proliferator-Activated Receptors Proteins 0.000 description 6
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 6
- 229910052783 alkali metal Inorganic materials 0.000 description 6
- 239000003638 chemical reducing agent Substances 0.000 description 6
- 229910052801 chlorine Inorganic materials 0.000 description 6
- 125000001309 chloro group Chemical group Cl* 0.000 description 6
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 6
- UAOMVDZJSHZZME-UHFFFAOYSA-N diisopropylamine Chemical compound CC(C)NC(C)C UAOMVDZJSHZZME-UHFFFAOYSA-N 0.000 description 6
- 150000002148 esters Chemical class 0.000 description 6
- 229940125753 fibrate Drugs 0.000 description 6
- 238000001914 filtration Methods 0.000 description 6
- 239000003112 inhibitor Substances 0.000 description 6
- KFZMGEQAYNKOFK-UHFFFAOYSA-N isopropyl alcohol Natural products CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 6
- 239000003446 ligand Substances 0.000 description 6
- 150000002632 lipids Chemical class 0.000 description 6
- 210000001589 microsome Anatomy 0.000 description 6
- AQNXZVKUFMJRPV-UHFFFAOYSA-N tert-butyl 2-[[4-(2-chloroacetyl)-1,3-thiazol-2-yl]sulfanyl]-2-methylpropanoate Chemical compound CC(C)(C)OC(=O)C(C)(C)SC1=NC(C(=O)CCl)=CS1 AQNXZVKUFMJRPV-UHFFFAOYSA-N 0.000 description 6
- 0 **CC(*=C=N)O Chemical compound **CC(*=C=N)O 0.000 description 5
- 108010023302 HDL Cholesterol Proteins 0.000 description 5
- 108010028554 LDL Cholesterol Proteins 0.000 description 5
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 5
- 150000001298 alcohols Chemical class 0.000 description 5
- 239000007864 aqueous solution Substances 0.000 description 5
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 5
- 235000012000 cholesterol Nutrition 0.000 description 5
- 150000008282 halocarbons Chemical class 0.000 description 5
- 125000004356 hydroxy functional group Chemical group O* 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 229910000027 potassium carbonate Inorganic materials 0.000 description 5
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 125000004076 pyridyl group Chemical group 0.000 description 5
- 125000000714 pyrimidinyl group Chemical group 0.000 description 5
- 239000002994 raw material Substances 0.000 description 5
- 238000010992 reflux Methods 0.000 description 5
- 125000000547 substituted alkyl group Chemical group 0.000 description 5
- SCYULBFZEHDVBN-UHFFFAOYSA-N 1,1-Dichloroethane Chemical compound CC(Cl)Cl SCYULBFZEHDVBN-UHFFFAOYSA-N 0.000 description 4
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- 108010000543 Cytochrome P-450 CYP2C9 Proteins 0.000 description 4
- 102100029358 Cytochrome P450 2C9 Human genes 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 4
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 4
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 4
- 241000700159 Rattus Species 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 4
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 4
- 230000001270 agonistic effect Effects 0.000 description 4
- 125000003158 alcohol group Chemical group 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 238000001035 drying Methods 0.000 description 4
- 238000001704 evaporation Methods 0.000 description 4
- 239000000706 filtrate Substances 0.000 description 4
- 125000005842 heteroatom Chemical group 0.000 description 4
- 229930195733 hydrocarbon Natural products 0.000 description 4
- 150000002430 hydrocarbons Chemical class 0.000 description 4
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 4
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 4
- 210000001853 liver microsome Anatomy 0.000 description 4
- 230000004060 metabolic process Effects 0.000 description 4
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 4
- 239000012044 organic layer Substances 0.000 description 4
- 229910052763 palladium Inorganic materials 0.000 description 4
- NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 4
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 4
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 4
- 229910000029 sodium carbonate Inorganic materials 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 125000003107 substituted aryl group Chemical group 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 4
- 239000003981 vehicle Substances 0.000 description 4
- XXZCIYUJYUESMD-UHFFFAOYSA-N 2-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]-3-(morpholin-4-ylmethyl)pyrazol-1-yl]-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C=1C(=NN(C=1)CC(=O)N1CC2=C(CC1)NN=N2)CN1CCOCC1 XXZCIYUJYUESMD-UHFFFAOYSA-N 0.000 description 3
- FUIAOWVHPJAKOE-UHFFFAOYSA-N 2-[[4-[2-[5-(4-fluorophenyl)pyridin-2-yl]oxy-1-hydroxyethyl]-1,3-thiazol-2-yl]sulfanyl]-2-methylpropanoic acid Chemical compound S1C(SC(C)(C)C(O)=O)=NC(C(O)COC=2N=CC(=CC=2)C=2C=CC(F)=CC=2)=C1 FUIAOWVHPJAKOE-UHFFFAOYSA-N 0.000 description 3
- YLZOPXRUQYQQID-UHFFFAOYSA-N 3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)-1-[4-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidin-5-yl]piperazin-1-yl]propan-1-one Chemical compound N1N=NC=2CN(CCC=21)CCC(=O)N1CCN(CC1)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F YLZOPXRUQYQQID-UHFFFAOYSA-N 0.000 description 3
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical group [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 101000741788 Homo sapiens Peroxisome proliferator-activated receptor alpha Proteins 0.000 description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
- SJRJJKPEHAURKC-UHFFFAOYSA-N N-Methylmorpholine Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 description 3
- 229910003251 Na K Inorganic materials 0.000 description 3
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 3
- 235000010724 Wisteria floribunda Nutrition 0.000 description 3
- 229910000288 alkali metal carbonate Inorganic materials 0.000 description 3
- 150000008041 alkali metal carbonates Chemical class 0.000 description 3
- 239000002168 alkylating agent Substances 0.000 description 3
- 229940100198 alkylating agent Drugs 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 238000001816 cooling Methods 0.000 description 3
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 3
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 229910052731 fluorine Inorganic materials 0.000 description 3
- 125000001153 fluoro group Chemical group F* 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- 102000054223 human PPARA Human genes 0.000 description 3
- 229910052740 iodine Inorganic materials 0.000 description 3
- 150000002576 ketones Chemical class 0.000 description 3
- NXPHGHWWQRMDIA-UHFFFAOYSA-M magnesium;carbanide;bromide Chemical compound [CH3-].[Mg+2].[Br-] NXPHGHWWQRMDIA-UHFFFAOYSA-M 0.000 description 3
- 239000002207 metabolite Substances 0.000 description 3
- 125000001624 naphthyl group Chemical group 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 235000019198 oils Nutrition 0.000 description 3
- 150000007530 organic bases Chemical class 0.000 description 3
- 125000002524 organometallic group Chemical group 0.000 description 3
- 230000004783 oxidative metabolism Effects 0.000 description 3
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 3
- LCPDWSOZIOUXRV-UHFFFAOYSA-N phenoxyacetic acid Chemical class OC(=O)COC1=CC=CC=C1 LCPDWSOZIOUXRV-UHFFFAOYSA-N 0.000 description 3
- 239000008363 phosphate buffer Substances 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 239000011541 reaction mixture Substances 0.000 description 3
- 238000011084 recovery Methods 0.000 description 3
- 125000006413 ring segment Chemical group 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- 229910000104 sodium hydride Inorganic materials 0.000 description 3
- 239000012312 sodium hydride Substances 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide Substances CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 2
- YBYIRNPNPLQARY-UHFFFAOYSA-N 1H-indene Natural products C1=CC=C2CC=CC2=C1 YBYIRNPNPLQARY-UHFFFAOYSA-N 0.000 description 2
- 125000004206 2,2,2-trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 description 2
- GQHTUMJGOHRCHB-UHFFFAOYSA-N 2,3,4,6,7,8,9,10-octahydropyrimido[1,2-a]azepine Chemical compound C1CCCCN2CCCN=C21 GQHTUMJGOHRCHB-UHFFFAOYSA-N 0.000 description 2
- PMYOXCVDPIXXOS-UHFFFAOYSA-N 2-[2-methyl-1-[(2-methylpropan-2-yl)oxy]-1-oxopropan-2-yl]sulfanyl-1,3-thiazole-4-carboxylic acid Chemical compound CC(C)(C)OC(=O)C(C)(C)SC1=NC(C(O)=O)=CS1 PMYOXCVDPIXXOS-UHFFFAOYSA-N 0.000 description 2
- VWVRASTUFJRTHW-UHFFFAOYSA-N 2-[3-(azetidin-3-yloxy)-4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]pyrazol-1-yl]-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound O=C(CN1C=C(C(OC2CNC2)=N1)C1=CN=C(NC2CC3=C(C2)C=CC=C3)N=C1)N1CCC2=C(C1)N=NN2 VWVRASTUFJRTHW-UHFFFAOYSA-N 0.000 description 2
- SXAMGRAIZSSWIH-UHFFFAOYSA-N 2-[3-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]-1,2,4-oxadiazol-5-yl]-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C1=NOC(=N1)CC(=O)N1CC2=C(CC1)NN=N2 SXAMGRAIZSSWIH-UHFFFAOYSA-N 0.000 description 2
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 2
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 2
- NDMZZQRNZFWMEZ-UHFFFAOYSA-N 5-bromo-1h-pyridin-2-one Chemical compound OC1=CC=C(Br)C=N1 NDMZZQRNZFWMEZ-UHFFFAOYSA-N 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 2
- 108010026925 Cytochrome P-450 CYP2C19 Proteins 0.000 description 2
- 108010000561 Cytochrome P-450 CYP2C8 Proteins 0.000 description 2
- 108010081668 Cytochrome P-450 CYP3A Proteins 0.000 description 2
- 102100036194 Cytochrome P450 2A6 Human genes 0.000 description 2
- 102100029363 Cytochrome P450 2C19 Human genes 0.000 description 2
- 102100029359 Cytochrome P450 2C8 Human genes 0.000 description 2
- 102100039205 Cytochrome P450 3A4 Human genes 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
- 102100039556 Galectin-4 Human genes 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 108010010234 HDL Lipoproteins Proteins 0.000 description 2
- 101000875170 Homo sapiens Cytochrome P450 2A6 Proteins 0.000 description 2
- 101000608765 Homo sapiens Galectin-4 Proteins 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 2
- JLTDJTHDQAWBAV-UHFFFAOYSA-N N,N-dimethylaniline Chemical compound CN(C)C1=CC=CC=C1 JLTDJTHDQAWBAV-UHFFFAOYSA-N 0.000 description 2
- 238000005481 NMR spectroscopy Methods 0.000 description 2
- 108020005497 Nuclear hormone receptor Proteins 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- 102000040945 Transcription factor Human genes 0.000 description 2
- 108091023040 Transcription factor Proteins 0.000 description 2
- 125000002252 acyl group Chemical group 0.000 description 2
- 150000008044 alkali metal hydroxides Chemical class 0.000 description 2
- 150000001340 alkali metals Chemical class 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 239000003524 antilipemic agent Substances 0.000 description 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 2
- 229960000516 bezafibrate Drugs 0.000 description 2
- IIBYAHWJQTYFKB-UHFFFAOYSA-N bezafibrate Chemical compound C1=CC(OC(C)(C)C(O)=O)=CC=C1CCNC(=O)C1=CC=C(Cl)C=C1 IIBYAHWJQTYFKB-UHFFFAOYSA-N 0.000 description 2
- 125000002619 bicyclic group Chemical group 0.000 description 2
- MCQRPQCQMGVWIQ-UHFFFAOYSA-N boron;methylsulfanylmethane Chemical compound [B].CSC MCQRPQCQMGVWIQ-UHFFFAOYSA-N 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 125000004218 chloromethyl group Chemical group [H]C([H])(Cl)* 0.000 description 2
- 229960001214 clofibrate Drugs 0.000 description 2
- KNHUKKLJHYUCFP-UHFFFAOYSA-N clofibrate Chemical compound CCOC(=O)C(C)(C)OC1=CC=C(Cl)C=C1 KNHUKKLJHYUCFP-UHFFFAOYSA-N 0.000 description 2
- 238000002425 crystallisation Methods 0.000 description 2
- 230000008025 crystallization Effects 0.000 description 2
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 2
- 238000000354 decomposition reaction Methods 0.000 description 2
- 239000002274 desiccant Substances 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 description 2
- 229940043279 diisopropylamine Drugs 0.000 description 2
- 238000001647 drug administration Methods 0.000 description 2
- 238000006911 enzymatic reaction Methods 0.000 description 2
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- 125000004216 fluoromethyl group Chemical group [H]C([H])(F)* 0.000 description 2
- 235000019253 formic acid Nutrition 0.000 description 2
- 150000004795 grignard reagents Chemical class 0.000 description 2
- 230000002140 halogenating effect Effects 0.000 description 2
- 125000005283 haloketone group Chemical group 0.000 description 2
- 125000000623 heterocyclic group Chemical group 0.000 description 2
- DKAGJZJALZXOOV-UHFFFAOYSA-N hydrate;hydrochloride Chemical compound O.Cl DKAGJZJALZXOOV-UHFFFAOYSA-N 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000001965 increasing effect Effects 0.000 description 2
- 125000003454 indenyl group Chemical group C1(C=CC2=CC=CC=C12)* 0.000 description 2
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 2
- 210000004731 jugular vein Anatomy 0.000 description 2
- 239000010410 layer Substances 0.000 description 2
- 229910052744 lithium Inorganic materials 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- QUXHCILOWRXCEO-UHFFFAOYSA-M magnesium;butane;chloride Chemical compound [Mg+2].[Cl-].CCC[CH2-] QUXHCILOWRXCEO-UHFFFAOYSA-M 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 229910052987 metal hydride Inorganic materials 0.000 description 2
- 150000004681 metal hydrides Chemical class 0.000 description 2
- 229940098779 methanesulfonic acid Drugs 0.000 description 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 2
- MBRDCTYJMBVJRI-UHFFFAOYSA-N methyl 2-[2-methyl-1-[(2-methylpropan-2-yl)oxy]-1-oxopropan-2-yl]sulfanyl-1,3-thiazole-4-carboxylate Chemical compound COC(=O)C1=CSC(SC(C)(C)C(=O)OC(C)(C)C)=N1 MBRDCTYJMBVJRI-UHFFFAOYSA-N 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- 239000011259 mixed solution Substances 0.000 description 2
- 125000004923 naphthylmethyl group Chemical group C1(=CC=CC2=CC=CC=C12)C* 0.000 description 2
- 150000002825 nitriles Chemical class 0.000 description 2
- 102000006255 nuclear receptors Human genes 0.000 description 2
- 108020004017 nuclear receptors Proteins 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 125000006340 pentafluoro ethyl group Chemical group FC(F)(F)C(F)(F)* 0.000 description 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 2
- 229920000053 polysorbate 80 Polymers 0.000 description 2
- 230000029279 positive regulation of transcription, DNA-dependent Effects 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 229910000105 potassium hydride Inorganic materials 0.000 description 2
- NTTOTNSKUYCDAV-UHFFFAOYSA-N potassium hydride Chemical compound [KH] NTTOTNSKUYCDAV-UHFFFAOYSA-N 0.000 description 2
- FVSKHRXBFJPNKK-UHFFFAOYSA-N propionitrile Chemical compound CCC#N FVSKHRXBFJPNKK-UHFFFAOYSA-N 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- SQGYOTSLMSWVJD-UHFFFAOYSA-N silver(1+) nitrate Chemical compound [Ag+].[O-]N(=O)=O SQGYOTSLMSWVJD-UHFFFAOYSA-N 0.000 description 2
- 239000012279 sodium borohydride Substances 0.000 description 2
- 229910000033 sodium borohydride Inorganic materials 0.000 description 2
- QDRKDTQENPPHOJ-UHFFFAOYSA-N sodium ethoxide Chemical compound [Na+].CC[O-] QDRKDTQENPPHOJ-UHFFFAOYSA-N 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 238000001308 synthesis method Methods 0.000 description 2
- 230000002194 synthesizing effect Effects 0.000 description 2
- MJGQMOVKYJMQOO-UHFFFAOYSA-N tert-butyl 2-[(4-acetyl-1,3-thiazol-2-yl)sulfanyl]-2-methylpropanoate Chemical compound CC(=O)C1=CSC(SC(C)(C)C(=O)OC(C)(C)C)=N1 MJGQMOVKYJMQOO-UHFFFAOYSA-N 0.000 description 2
- RUBNWSGDNDIOMK-UHFFFAOYSA-N tert-butyl 2-[[4-[2-[4-(4-fluorophenyl)phenoxy]acetyl]-1,3-thiazol-2-yl]sulfanyl]-2-methylpropanoate Chemical compound S1C(SC(C)(C)C(=O)OC(C)(C)C)=NC(C(=O)COC=2C=CC(=CC=2)C=2C=CC(F)=CC=2)=C1 RUBNWSGDNDIOMK-UHFFFAOYSA-N 0.000 description 2
- FQFILJKFZCVHNH-UHFFFAOYSA-N tert-butyl n-[3-[(5-bromo-2-chloropyrimidin-4-yl)amino]propyl]carbamate Chemical compound CC(C)(C)OC(=O)NCCCNC1=NC(Cl)=NC=C1Br FQFILJKFZCVHNH-UHFFFAOYSA-N 0.000 description 2
- DPKBAXPHAYBPRL-UHFFFAOYSA-M tetrabutylazanium;iodide Chemical compound [I-].CCCC[N+](CCCC)(CCCC)CCCC DPKBAXPHAYBPRL-UHFFFAOYSA-M 0.000 description 2
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 2
- 238000004809 thin layer chromatography Methods 0.000 description 2
- 150000003568 thioethers Chemical class 0.000 description 2
- 125000005951 trifluoromethanesulfonyloxy group Chemical group 0.000 description 2
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 2
- COIOYMYWGDAQPM-UHFFFAOYSA-N tris(2-methylphenyl)phosphane Chemical compound CC1=CC=CC=C1P(C=1C(=CC=CC=1)C)C1=CC=CC=C1C COIOYMYWGDAQPM-UHFFFAOYSA-N 0.000 description 2
- RQEUFEKYXDPUSK-SSDOTTSWSA-N (1R)-1-phenylethanamine Chemical compound C[C@@H](N)C1=CC=CC=C1 RQEUFEKYXDPUSK-SSDOTTSWSA-N 0.000 description 1
- CYPYTURSJDMMMP-WVCUSYJESA-N (1e,4e)-1,5-diphenylpenta-1,4-dien-3-one;palladium Chemical compound [Pd].[Pd].C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1 CYPYTURSJDMMMP-WVCUSYJESA-N 0.000 description 1
- PAORVUMOXXAMPL-SECBINFHSA-N (2s)-3,3,3-trifluoro-2-methoxy-2-phenylpropanoyl chloride Chemical compound CO[C@](C(Cl)=O)(C(F)(F)F)C1=CC=CC=C1 PAORVUMOXXAMPL-SECBINFHSA-N 0.000 description 1
- ZGGHKIMDNBDHJB-NRFPMOEYSA-M (3R,5S)-fluvastatin sodium Chemical compound [Na+].C12=CC=CC=C2N(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC([O-])=O)=C1C1=CC=C(F)C=C1 ZGGHKIMDNBDHJB-NRFPMOEYSA-M 0.000 description 1
- BHQCQFFYRZLCQQ-UHFFFAOYSA-N (3alpha,5alpha,7alpha,12alpha)-3,7,12-trihydroxy-cholan-24-oic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 BHQCQFFYRZLCQQ-UHFFFAOYSA-N 0.000 description 1
- PHBVXHIVWULVNF-UHFFFAOYSA-N (4-fluorophenoxy)boronic acid Chemical compound OB(O)OC1=CC=C(F)C=C1 PHBVXHIVWULVNF-UHFFFAOYSA-N 0.000 description 1
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 description 1
- KZPYGQFFRCFCPP-UHFFFAOYSA-N 1,1'-bis(diphenylphosphino)ferrocene Chemical compound [Fe+2].C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1 KZPYGQFFRCFCPP-UHFFFAOYSA-N 0.000 description 1
- 125000004529 1,2,3-triazinyl group Chemical group N1=NN=C(C=C1)* 0.000 description 1
- 125000004504 1,2,4-oxadiazolyl group Chemical group 0.000 description 1
- 125000004514 1,2,4-thiadiazolyl group Chemical group 0.000 description 1
- 125000004530 1,2,4-triazinyl group Chemical group N1=NC(=NC=C1)* 0.000 description 1
- 125000002030 1,2-phenylene group Chemical group [H]C1=C([H])C([*:1])=C([*:2])C([H])=C1[H] 0.000 description 1
- 125000001781 1,3,4-oxadiazolyl group Chemical group 0.000 description 1
- 125000003363 1,3,5-triazinyl group Chemical group N1=C(N=CN=C1)* 0.000 description 1
- ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 description 1
- VMKAFJQFKBASMU-UHFFFAOYSA-N 1-methyl-3,3-diphenyl-3a,4,5,6-tetrahydropyrrolo[1,2-c][1,3,2]oxazaborole Chemical compound C12CCCN2B(C)OC1(C=1C=CC=CC=1)C1=CC=CC=C1 VMKAFJQFKBASMU-UHFFFAOYSA-N 0.000 description 1
- 125000004343 1-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])(*)C([H])([H])[H] 0.000 description 1
- WGLLSSPDPJPLOR-UHFFFAOYSA-N 2,3-dimethylbut-2-ene Chemical group CC(C)=C(C)C WGLLSSPDPJPLOR-UHFFFAOYSA-N 0.000 description 1
- QMCZHYRIPXNIBG-UHFFFAOYSA-N 2-(1,3-thiazol-2-yl)ethanethioic s-acid Chemical class OC(=S)CC1=NC=CS1 QMCZHYRIPXNIBG-UHFFFAOYSA-N 0.000 description 1
- NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 1
- WWSJZGAPAVMETJ-UHFFFAOYSA-N 2-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]-3-ethoxypyrazol-1-yl]-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C=1C(=NN(C=1)CC(=O)N1CC2=C(CC1)NN=N2)OCC WWSJZGAPAVMETJ-UHFFFAOYSA-N 0.000 description 1
- IYWJDGCYTCCUSI-UHFFFAOYSA-N 2-[[4-[2-[4-(4-fluorophenyl)phenoxy]ethyl]-1,3-thiazol-2-yl]sulfanyl]-2-methylpropanoic acid Chemical compound S1C(SC(C)(C)C(O)=O)=NC(CCOC=2C=CC(=CC=2)C=2C=CC(F)=CC=2)=C1 IYWJDGCYTCCUSI-UHFFFAOYSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- LAXBNTIAOJWAOP-UHFFFAOYSA-N 2-chlorobiphenyl Chemical group ClC1=CC=CC=C1C1=CC=CC=C1 LAXBNTIAOJWAOP-UHFFFAOYSA-N 0.000 description 1
- NEAQRZUHTPSBBM-UHFFFAOYSA-N 2-hydroxy-3,3-dimethyl-7-nitro-4h-isoquinolin-1-one Chemical compound C1=C([N+]([O-])=O)C=C2C(=O)N(O)C(C)(C)CC2=C1 NEAQRZUHTPSBBM-UHFFFAOYSA-N 0.000 description 1
- MYHNUQVKTSTVDI-UHFFFAOYSA-N 2-methyl-2-[(2-methylpropan-2-yl)oxy]propane;potassium Chemical compound [K].CC(C)(C)OC(C)(C)C MYHNUQVKTSTVDI-UHFFFAOYSA-N 0.000 description 1
- 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 1
- MOTOSAGBNXXRRE-UHFFFAOYSA-N 2-phenylsulfanylacetic acid Chemical class OC(=O)CSC1=CC=CC=C1 MOTOSAGBNXXRRE-UHFFFAOYSA-N 0.000 description 1
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 125000006479 2-pyridyl methyl group Chemical group [H]C1=C([H])C([H])=C([H])C(=N1)C([H])([H])* 0.000 description 1
- XMIIGOLPHOKFCH-UHFFFAOYSA-N 3-phenylpropionic acid Chemical class OC(=O)CCC1=CC=CC=C1 XMIIGOLPHOKFCH-UHFFFAOYSA-N 0.000 description 1
- QSJNKJGPJVOGPK-UHFFFAOYSA-N 4-(4-fluorophenyl)phenol Chemical compound C1=CC(O)=CC=C1C1=CC=C(F)C=C1 QSJNKJGPJVOGPK-UHFFFAOYSA-N 0.000 description 1
- FPWNLURCHDRMHC-UHFFFAOYSA-N 4-chlorobiphenyl Chemical group C1=CC(Cl)=CC=C1C1=CC=CC=C1 FPWNLURCHDRMHC-UHFFFAOYSA-N 0.000 description 1
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 108010071619 Apolipoproteins Proteins 0.000 description 1
- 102000007592 Apolipoproteins Human genes 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 125000005914 C6-C14 aryloxy group Chemical group 0.000 description 1
- 239000004380 Cholic acid Substances 0.000 description 1
- BMOVQUBVGICXQN-UHFFFAOYSA-N Clinofibrate Chemical compound C1=CC(OC(C)(CC)C(O)=O)=CC=C1C1(C=2C=CC(OC(C)(CC)C(O)=O)=CC=2)CCCCC1 BMOVQUBVGICXQN-UHFFFAOYSA-N 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 108010074922 Cytochrome P-450 CYP1A2 Proteins 0.000 description 1
- 108010020070 Cytochrome P-450 CYP2B6 Proteins 0.000 description 1
- 108010001237 Cytochrome P-450 CYP2D6 Proteins 0.000 description 1
- 108010001202 Cytochrome P-450 CYP2E1 Proteins 0.000 description 1
- 102100026533 Cytochrome P450 1A2 Human genes 0.000 description 1
- 102100038739 Cytochrome P450 2B6 Human genes 0.000 description 1
- 102100021704 Cytochrome P450 2D6 Human genes 0.000 description 1
- 102100024889 Cytochrome P450 2E1 Human genes 0.000 description 1
- NBSCHQHZLSJFNQ-GASJEMHNSA-N D-Glucose 6-phosphate Chemical compound OC1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H](O)[C@H]1O NBSCHQHZLSJFNQ-GASJEMHNSA-N 0.000 description 1
- 230000004568 DNA-binding Effects 0.000 description 1
- 102100037458 Dephospho-CoA kinase Human genes 0.000 description 1
- XBPCUCUWBYBCDP-UHFFFAOYSA-N Dicyclohexylamine Chemical compound C1CCCCC1NC1CCCCC1 XBPCUCUWBYBCDP-UHFFFAOYSA-N 0.000 description 1
- ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical class CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 208000010201 Exanthema Diseases 0.000 description 1
- SMKWJOYJMSWUMD-QGZVFWFLSA-N FC1=CC=C(C=C1)C1=CC=C(C=C1)OC[C@@H](O)C=1N=CSC1 Chemical compound FC1=CC=C(C=C1)C1=CC=C(C=C1)OC[C@@H](O)C=1N=CSC1 SMKWJOYJMSWUMD-QGZVFWFLSA-N 0.000 description 1
- 108010022535 Farnesyl-Diphosphate Farnesyltransferase Proteins 0.000 description 1
- 102000000476 Fatty Acid Transport Proteins Human genes 0.000 description 1
- 108010055870 Fatty Acid Transport Proteins Proteins 0.000 description 1
- 108090000331 Firefly luciferases Proteins 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- VFRROHXSMXFLSN-UHFFFAOYSA-N Glc6P Natural products OP(=O)(O)OCC(O)C(O)C(O)C(O)C=O VFRROHXSMXFLSN-UHFFFAOYSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 1
- 208000001748 Hyperlipoproteinemia Type V Diseases 0.000 description 1
- 206010022489 Insulin Resistance Diseases 0.000 description 1
- 238000008214 LDL Cholesterol Methods 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 102000003960 Ligases Human genes 0.000 description 1
- 108090000364 Ligases Proteins 0.000 description 1
- 239000012097 Lipofectamine 2000 Substances 0.000 description 1
- 108010013563 Lipoprotein Lipase Proteins 0.000 description 1
- 102100022119 Lipoprotein lipase Human genes 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- 239000012448 Lithium borohydride Substances 0.000 description 1
- 108060001084 Luciferase Proteins 0.000 description 1
- 239000005089 Luciferase Substances 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 150000001204 N-oxides Chemical class 0.000 description 1
- XJLXINKUBYWONI-NNYOXOHSSA-N NADP zwitterion Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](OP(O)(O)=O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 XJLXINKUBYWONI-NNYOXOHSSA-N 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 102000000536 PPAR gamma Human genes 0.000 description 1
- 108010016731 PPAR gamma Proteins 0.000 description 1
- 206010033645 Pancreatitis Diseases 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 108010052090 Renilla Luciferases Proteins 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 101000650578 Salmonella phage P22 Regulatory protein C3 Proteins 0.000 description 1
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 1
- JLRNKCZRCMIVKA-UHFFFAOYSA-N Simfibrate Chemical compound C=1C=C(Cl)C=CC=1OC(C)(C)C(=O)OCCCOC(=O)C(C)(C)OC1=CC=C(Cl)C=C1 JLRNKCZRCMIVKA-UHFFFAOYSA-N 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 101001040920 Triticum aestivum Alpha-amylase inhibitor 0.28 Proteins 0.000 description 1
- 206010060749 Type I hyperlipidaemia Diseases 0.000 description 1
- 206010060751 Type III hyperlipidaemia Diseases 0.000 description 1
- 206010045263 Type IIb hyperlipidaemia Diseases 0.000 description 1
- 206010060753 Type IV hyperlipidaemia Diseases 0.000 description 1
- 206010060755 Type V hyperlipidaemia Diseases 0.000 description 1
- DGYIJVNZSDYBOE-UHFFFAOYSA-N [CH2]C1=CC=NC=C1 Chemical group [CH2]C1=CC=NC=C1 DGYIJVNZSDYBOE-UHFFFAOYSA-N 0.000 description 1
- XJLXINKUBYWONI-DQQFMEOOSA-N [[(2r,3r,4r,5r)-5-(6-aminopurin-9-yl)-3-hydroxy-4-phosphonooxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [(2s,3r,4s,5s)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl phosphate Chemical compound NC(=O)C1=CC=C[N+]([C@@H]2[C@H]([C@@H](O)[C@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](OP(O)(O)=O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 XJLXINKUBYWONI-DQQFMEOOSA-N 0.000 description 1
- 206010000059 abdominal discomfort Diseases 0.000 description 1
- GPWHDDKQSYOYBF-UHFFFAOYSA-N ac1l2u0q Chemical compound Br[Br-]Br GPWHDDKQSYOYBF-UHFFFAOYSA-N 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- VFRROHXSMXFLSN-KCDKBNATSA-N aldehydo-D-galactose 6-phosphate Chemical compound OP(=O)(O)OC[C@@H](O)[C@H](O)[C@H](O)[C@@H](O)C=O VFRROHXSMXFLSN-KCDKBNATSA-N 0.000 description 1
- 229910000318 alkali metal phosphate Inorganic materials 0.000 description 1
- 125000003342 alkenyl group Chemical group 0.000 description 1
- 150000004703 alkoxides Chemical class 0.000 description 1
- 125000005907 alkyl ester group Chemical group 0.000 description 1
- 150000001350 alkyl halides Chemical class 0.000 description 1
- 230000002152 alkylating effect Effects 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-N ammonia Natural products N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000001315 anti-hyperlipaemic effect Effects 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 125000006615 aromatic heterocyclic group Chemical group 0.000 description 1
- 150000004945 aromatic hydrocarbons Chemical class 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 125000002393 azetidinyl group Chemical group 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 229940092714 benzenesulfonic acid Drugs 0.000 description 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
- 125000004604 benzisothiazolyl group Chemical group S1N=C(C2=C1C=CC=C2)* 0.000 description 1
- 125000004603 benzisoxazolyl group Chemical group O1N=C(C2=C1C=CC=C2)* 0.000 description 1
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 125000004622 benzoxazinyl group Chemical group O1NC(=CC2=C1C=CC=C2)* 0.000 description 1
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 230000027455 binding Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- YNHIGQDRGKUECZ-UHFFFAOYSA-L bis(triphenylphosphine)palladium(ii) dichloride Chemical compound [Cl-].[Cl-].[Pd+2].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 YNHIGQDRGKUECZ-UHFFFAOYSA-L 0.000 description 1
- UORVGPXVDQYIDP-BJUDXGSMSA-N borane Chemical class [10BH3] UORVGPXVDQYIDP-BJUDXGSMSA-N 0.000 description 1
- 150000001639 boron compounds Chemical class 0.000 description 1
- UWTDFICHZKXYAC-UHFFFAOYSA-N boron;oxolane Chemical compound [B].C1CCOC1 UWTDFICHZKXYAC-UHFFFAOYSA-N 0.000 description 1
- RDHPKYGYEGBMSE-UHFFFAOYSA-N bromoethane Chemical compound CCBr RDHPKYGYEGBMSE-UHFFFAOYSA-N 0.000 description 1
- 125000004799 bromophenyl group Chemical group 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- WXMZPPIDLJRXNK-UHFFFAOYSA-N butyl(diphenyl)phosphane Chemical compound C=1C=CC=CC=1P(CCCC)C1=CC=CC=C1 WXMZPPIDLJRXNK-UHFFFAOYSA-N 0.000 description 1
- 229910052792 caesium Inorganic materials 0.000 description 1
- TVFDJXOCXUVLDH-UHFFFAOYSA-N caesium atom Chemical compound [Cs] TVFDJXOCXUVLDH-UHFFFAOYSA-N 0.000 description 1
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 1
- 229910000024 caesium carbonate Inorganic materials 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 238000010568 chiral column chromatography Methods 0.000 description 1
- 238000005660 chlorination reaction Methods 0.000 description 1
- 150000001805 chlorine compounds Chemical class 0.000 description 1
- FOCAUTSVDIKZOP-UHFFFAOYSA-N chloroacetic acid Chemical compound OC(=O)CCl FOCAUTSVDIKZOP-UHFFFAOYSA-N 0.000 description 1
- 229940106681 chloroacetic acid Drugs 0.000 description 1
- 125000000068 chlorophenyl group Chemical group 0.000 description 1
- 235000019416 cholic acid Nutrition 0.000 description 1
- BHQCQFFYRZLCQQ-OELDTZBJSA-N cholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 BHQCQFFYRZLCQQ-OELDTZBJSA-N 0.000 description 1
- 229960002471 cholic acid Drugs 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 125000004230 chromenyl group Chemical group O1C(C=CC2=CC=CC=C12)* 0.000 description 1
- 125000000259 cinnolinyl group Chemical group N1=NC(=CC2=CC=CC=C12)* 0.000 description 1
- 229950003072 clinofibrate Drugs 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 238000006114 decarboxylation reaction Methods 0.000 description 1
- 125000002704 decyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 238000007257 deesterification reaction Methods 0.000 description 1
- KXGVEGMKQFWNSR-UHFFFAOYSA-N deoxycholic acid Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 KXGVEGMKQFWNSR-UHFFFAOYSA-N 0.000 description 1
- 108010049285 dephospho-CoA kinase Proteins 0.000 description 1
- XXTZHYXQVWRADW-UHFFFAOYSA-N diazomethanone Chemical compound [N]N=C=O XXTZHYXQVWRADW-UHFFFAOYSA-N 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- VAYGXNSJCAHWJZ-UHFFFAOYSA-N dimethyl sulfate Chemical compound COS(=O)(=O)OC VAYGXNSJCAHWJZ-UHFFFAOYSA-N 0.000 description 1
- FDPIMTJIUBPUKL-UHFFFAOYSA-N dimethylacetone Natural products CCC(=O)CC FDPIMTJIUBPUKL-UHFFFAOYSA-N 0.000 description 1
- ZZVUWRFHKOJYTH-UHFFFAOYSA-N diphenhydramine Chemical group C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 ZZVUWRFHKOJYTH-UHFFFAOYSA-N 0.000 description 1
- AAXGWYDSLJUQLN-UHFFFAOYSA-N diphenyl(propyl)phosphane Chemical compound C=1C=CC=CC=1P(CCC)C1=CC=CC=C1 AAXGWYDSLJUQLN-UHFFFAOYSA-N 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000000132 electrospray ionisation Methods 0.000 description 1
- 230000032050 esterification Effects 0.000 description 1
- 238000005886 esterification reaction Methods 0.000 description 1
- ASBMXLVNMWPFKF-LLVKDONJSA-N ethyl (2R)-3,3,3-trifluoro-2-methoxy-2-phenylpropanoate Chemical compound CCOC(=O)[C@@](OC)(C(F)(F)F)C1=CC=CC=C1 ASBMXLVNMWPFKF-LLVKDONJSA-N 0.000 description 1
- 125000004494 ethyl ester group Chemical group 0.000 description 1
- 125000000816 ethylene group Chemical group [H]C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 230000004129 fatty acid metabolism Effects 0.000 description 1
- 229960002297 fenofibrate Drugs 0.000 description 1
- YMTINGFKWWXKFG-UHFFFAOYSA-N fenofibrate Chemical compound C1=CC(OC(C)(C)C(=O)OC(C)C)=CC=C1C(=O)C1=CC=C(Cl)C=C1 YMTINGFKWWXKFG-UHFFFAOYSA-N 0.000 description 1
- 229960003765 fluvastatin Drugs 0.000 description 1
- 238000005187 foaming Methods 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 238000007446 glucose tolerance test Methods 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 125000004438 haloalkoxy group Chemical group 0.000 description 1
- 125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 238000000589 high-performance liquid chromatography-mass spectrometry Methods 0.000 description 1
- USZLCYNVCCDPLQ-UHFFFAOYSA-N hydron;n-methoxymethanamine;chloride Chemical compound Cl.CNOC USZLCYNVCCDPLQ-UHFFFAOYSA-N 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 1
- 238000013095 identification testing Methods 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 1
- 125000003387 indolinyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 125000001977 isobenzofuranyl group Chemical group C=1(OC=C2C=CC=CC12)* 0.000 description 1
- 125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000005956 isoquinolyl group Chemical group 0.000 description 1
- 125000001786 isothiazolyl group Chemical group 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 230000037356 lipid metabolism Effects 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 230000005976 liver dysfunction Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- DVSDBMFJEQPWNO-UHFFFAOYSA-N methyllithium Chemical compound C[Li] DVSDBMFJEQPWNO-UHFFFAOYSA-N 0.000 description 1
- 125000004998 naphthylethyl group Chemical group C1(=CC=CC2=CC=CC=C12)CC* 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 229910052759 nickel Inorganic materials 0.000 description 1
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- 125000001400 nonyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000012053 oil suspension Substances 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- YJVFFLUZDVXJQI-UHFFFAOYSA-L palladium(ii) acetate Chemical compound [Pd+2].CC([O-])=O.CC([O-])=O YJVFFLUZDVXJQI-UHFFFAOYSA-L 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 239000003614 peroxisome proliferator Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000003444 phase transfer catalyst Substances 0.000 description 1
- 229940117803 phenethylamine Drugs 0.000 description 1
- 125000004346 phenylpentyl group Chemical group C1(=CC=CC=C1)CCCCC* 0.000 description 1
- 125000004344 phenylpropyl group Chemical group 0.000 description 1
- 125000004592 phthalazinyl group Chemical group C1(=NN=CC2=CC=CC=C12)* 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 description 1
- 229910000160 potassium phosphate Inorganic materials 0.000 description 1
- 235000011009 potassium phosphates Nutrition 0.000 description 1
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000011533 pre-incubation Methods 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- 125000002098 pyridazinyl group Chemical group 0.000 description 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 1
- 125000005493 quinolyl group Chemical group 0.000 description 1
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 1
- 206010037844 rash Diseases 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 238000001226 reprecipitation Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 239000012679 serum free medium Substances 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 238000010898 silica gel chromatography Methods 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- 229910001961 silver nitrate Inorganic materials 0.000 description 1
- 229960004058 simfibrate Drugs 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- GGCZERPQGJTIQP-UHFFFAOYSA-N sodium;9,10-dioxoanthracene-2-sulfonic acid Chemical compound [Na+].C1=CC=C2C(=O)C3=CC(S(=O)(=O)O)=CC=C3C(=O)C2=C1 GGCZERPQGJTIQP-UHFFFAOYSA-N 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- QWCJHSGMANYXCW-UHFFFAOYSA-N sulfaphenazole Chemical compound C1=CC(N)=CC=C1S(=O)(=O)NC1=CC=NN1C1=CC=CC=C1 QWCJHSGMANYXCW-UHFFFAOYSA-N 0.000 description 1
- 229960004818 sulfaphenazole Drugs 0.000 description 1
- 150000003462 sulfoxides Chemical class 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- BZYGSRVFFGTAOK-UHFFFAOYSA-N tert-butyl 2-[[4-(2-bromoacetyl)-1,3-thiazol-2-yl]sulfanyl]-2-methylpropanoate Chemical compound CC(C)(C)OC(=O)C(C)(C)SC1=NC(C(=O)CBr)=CS1 BZYGSRVFFGTAOK-UHFFFAOYSA-N 0.000 description 1
- VMFKAKVIVHSNEA-UHFFFAOYSA-N tert-butyl 2-[[4-[2-(5-bromopyridin-2-yl)oxyacetyl]-1,3-thiazol-2-yl]sulfanyl]-2-methylpropanoate Chemical compound S1C(SC(C)(C)C(=O)OC(C)(C)C)=NC(C(=O)COC=2N=CC(Br)=CC=2)=C1 VMFKAKVIVHSNEA-UHFFFAOYSA-N 0.000 description 1
- DUXIRHWSRAIXEC-UHFFFAOYSA-N tert-butyl 2-[[4-[2-[4-(4-chlorophenyl)phenoxy]acetyl]-1,3-thiazol-2-yl]sulfanyl]-2-methylpropanoate Chemical compound S1C(SC(C)(C)C(=O)OC(C)(C)C)=NC(C(=O)COC=2C=CC(=CC=2)C=2C=CC(Cl)=CC=2)=C1 DUXIRHWSRAIXEC-UHFFFAOYSA-N 0.000 description 1
- AHHKJJJOQIHBQI-UHFFFAOYSA-N tert-butyl 2-[[4-[2-[4-(4-fluorophenyl)phenoxy]-1-hydroxyethyl]-1,3-thiazol-2-yl]sulfanyl]-2-methylpropanoate Chemical compound S1C(SC(C)(C)C(=O)OC(C)(C)C)=NC(C(O)COC=2C=CC(=CC=2)C=2C=CC(F)=CC=2)=C1 AHHKJJJOQIHBQI-UHFFFAOYSA-N 0.000 description 1
- PLDVLOOADCCIME-UHFFFAOYSA-N tert-butyl 2-[[4-[methoxy(methyl)carbamoyl]-1,3-thiazol-2-yl]sulfanyl]-2-methylpropanoate Chemical compound CON(C)C(=O)C1=CSC(SC(C)(C)C(=O)OC(C)(C)C)=N1 PLDVLOOADCCIME-UHFFFAOYSA-N 0.000 description 1
- KVWOTUDBCFBGFJ-UHFFFAOYSA-N tert-butyl 2-methylpropanoate Chemical compound CC(C)C(=O)OC(C)(C)C KVWOTUDBCFBGFJ-UHFFFAOYSA-N 0.000 description 1
- JAELLLITIZHOGQ-UHFFFAOYSA-N tert-butyl propanoate Chemical compound CCC(=O)OC(C)(C)C JAELLLITIZHOGQ-UHFFFAOYSA-N 0.000 description 1
- 125000000383 tetramethylene group Chemical group [H]C([H])([*:1])C([H])([H])C([H])([H])C([H])([H])[*:2] 0.000 description 1
- CZDYPVPMEAXLPK-UHFFFAOYSA-N tetramethylsilane Chemical compound C[Si](C)(C)C CZDYPVPMEAXLPK-UHFFFAOYSA-N 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 125000005306 thianaphthenyl group Chemical group 0.000 description 1
- 125000000437 thiazol-2-yl group Chemical group [H]C1=C([H])N=C(*)S1 0.000 description 1
- 150000003548 thiazolidines Chemical class 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- 125000003396 thiol group Chemical group [H]S* 0.000 description 1
- 150000003573 thiols Chemical class 0.000 description 1
- 125000005505 thiomorpholino group Chemical group 0.000 description 1
- 150000003606 tin compounds Chemical class 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 125000001425 triazolyl group Chemical group 0.000 description 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 1
- ZNEOHLHCKGUAEB-UHFFFAOYSA-N trimethylphenylammonium Chemical compound C[N+](C)(C)C1=CC=CC=C1 ZNEOHLHCKGUAEB-UHFFFAOYSA-N 0.000 description 1
- PRXNKYBFWAWBNZ-UHFFFAOYSA-N trimethylphenylammonium tribromide Chemical compound Br[Br-]Br.C[N+](C)(C)C1=CC=CC=C1 PRXNKYBFWAWBNZ-UHFFFAOYSA-N 0.000 description 1
- 229910000404 tripotassium phosphate Inorganic materials 0.000 description 1
- 235000019798 tripotassium phosphate Nutrition 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/36—Sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Definitions
- the present invention relates to a novel carboxylic acid derivative containing a thiazole ring and a medicine containing the same as an active ingredient.
- Peroxisome proliferator-activated receptor is a nuclear receptor that was cloned in 1990 as a receptor that responds to peroxisome proliferators. Other nuclear receptors, retinoidorX receptor (RXR) and heterodimers And activate various target genes as transcription factors.
- RXR retinoidorX receptor
- Fibrate drugs are widely used as antihyperlipidemic drugs, and clofibrate, clofibrate aluminum, simfibrate, clinofibrate, etc. have been used so far, but are now said to be the second generation.
- Bezafibrate (Bezator SR (registered trademark), Bezalip (registered trademark)) and fenofibrate (Ripidil (registered trademark), Tricore (registered trademark)) are widely used.
- Fibrate drugs activate PPAR ⁇ to activate genes associated with fatty acid metabolism (acyl CoA synthase, lipoprotein lipase, fatty acid transport protein, etc.), apolipoproteins involved in neutral fat (TG) and cholesterol metabolism ( AI, AII, AV, CIII) are known to show high efficacy as therapeutic drugs for hyperlipidemia because they regulate the expression of genes, decrease TG and LDL cholesterol, and increase HDL cholesterol.
- Patent Document 1 and Non-Patent Document 2 include (phenylthio) acetic acid derivatives
- Patent Document 2 and Non-Patent Document 3 include 3-phenylpropionic acid derivatives
- Patent Document 3 and Non-Patent Document 4 Is a phenoxyacetic acid derivative
- Patent Document 4 is a phenoxyacetic acid derivative
- Patent Document 5 and Non-Patent Document 5 are 2,2-dichloroalkanecarboxylic acid derivatives
- Patent Document 6 is 1,3-dioxane-2.
- Patent Document 7 discloses phenoxyacetic acid derivatives
- Patent Document 8 discloses (1,3-thiazol-2-yl) -thioacetic acid derivatives.
- An object of the present invention is to provide a compound having a PPAR ⁇ agonistic activity and useful as a prophylactic and / or therapeutic agent for hyperlipidemia and a compound useful as an intermediate thereof.
- the present inventor has conducted research focusing on the role of PPAR ⁇ in relation to lipid metabolism for the purpose of creating a drug useful as a prophylactic and / or therapeutic agent for hyperlipidemia. As a result, the following general formula (I) is shown. The present inventors have found that the compound has an excellent PPAR ⁇ agonistic action and exhibits a lipid lowering action, and further, found a compound useful as a synthetic intermediate for these compounds, thereby completing the present invention.
- R 1 and R 2 are the same or different and each represents a hydrogen atom or an alkyl group which may have a substituent, or R 1 and R 2 are bonded to each other and have a substituent.
- Forming a good cycloalkyl group R 3 represents a hydrogen atom or an alkyl group which may have a substituent; R 4 represents a hydrogen atom, an alkyl group which may have a substituent, or an aryl group which may have a substituent; m represents an integer of 0 to 3;
- X represents a bond, an oxygen atom or a sulfur atom;
- Y represents a carbonyl group or a group represented by —CH (OR 5 ) — (wherein R 5 represents a hydrogen atom or an alkyl group which may have a substituent);
- Z is A halogen atom, An alkyl group which may have a substituent, A cycloalkyl group optionally having a substituent, An aryl group which may have
- R 1 , R 2 , R 3 , R 4 , m, X, Y, Z are as defined above. Or a pharmaceutically acceptable salt thereof, or a hydrate or a solvate thereof;
- R 1 and R 2 are the same or different and each represents a C 1-15 alkyl group, R 3 represents a hydrogen atom or a C 1-15 alkyl group; R 4 represents a hydrogen atom; m represents 0; X represents a bond or an oxygen atom; Y represents a carbonyl group or a group represented by —CH (OR 5 ) — (wherein R 5 represents a hydrogen atom or a C 1-15 alkyl group); Z represents a halogen atom, a C 1-15 alkyl group, an optionally substituted C 6-14 aryl group or an optionally substituted heteroaryl group;
- R 6 , R 7 , R 8 , R 9 and R 10 are the same or different and each represents a hydrogen atom, a C 1-6 alkyl group, a halo-C 1-6 alkyl group, a C 6-14 aryl group or a halo-C.
- a 6-14 aryl group, E 1 represents an oxygen atom, a sulfur atom or —NR 20 — (wherein R 20 represents a hydrogen atom, a C 1-6 alkyl group, a C 3-7 cycloalkyl group, a C 6-14 aryl group, a C 6-14 An aryl-C 1-6 alkyl group or a heteroaryl-C 1-6 alkyl group).
- a pharmaceutical composition comprising the carboxylic acid derivative according to any one of [1] to [6] or a pharmaceutically acceptable salt or hydrate or solvate thereof, and a pharmaceutically acceptable carrier. object; [10] Administering the carboxylic acid derivative according to any one of [1] to [6] or a pharmaceutically acceptable salt thereof, or a hydrate or solvate thereof to a subject in need thereof.
- a method for preventing and / or treating a disease selected from hyperlipidemia, hyperlipidemia associated with diabetes, arteriosclerosis, ischemic heart disease and diabetes [11] Any one of [1] to [6] for use in the prevention and / or treatment of a disease selected from hyperlipidemia, hyperlipidemia associated with diabetes, arteriosclerosis, ischemic heart disease and diabetes Or a pharmaceutically acceptable salt thereof, or a hydrate or solvate thereof.
- a compound having a PPAR ⁇ agonistic action and useful as a prophylactic and / or therapeutic drug for hyperlipidemia can be provided.
- an intermediate useful for synthesizing the above compound can be provided.
- alkyl group of the “optionally substituted alkyl group” represented by R 1 and R 2 is usually a linear or branched alkyl group having 1 to 15 carbon atoms (C 1 -15 alkyl group), for example, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl, isopentyl, neopentyl, hexyl, heptyl, octyl, nonyl, decyl and the like.
- C 1 -15 alkyl group for example, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl, isopentyl, neopentyl, hexyl, heptyl, octyl, nonyl, decyl and the
- a C 1-6 alkyl group such as methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl or pentyl, more preferably methyl or ethyl, most preferably methyl It is.
- alkyl group optionally having substituent (s) may have, (1) a halogen atom, (2) C 1-15 alkyl (preferably C 1-6 alkyl), (3) Halo-C 1-15 alkyl, (4) (i) a halogen atom, (ii) hydroxy, (iii) Nitro, (iv) cyano, (v) amino, (vi) C 1-15 alkyl, (vii) halo-C 1-15 alkyl, (viii) C 1-15 alkoxy and (ix) C 6-14 aryl optionally having 1 to 3 substituents selected from the group consisting of halo-C 1-15 alkoxy, (5) (i) a halogen atom, (ii) hydroxy, (iii) Nitro, (iv) cyano, (v) amino, (vi) C 1-15 alkyl, (vii) halo-C 1-15 alkyl, (viii) C 1-15 alkoxy and (ix) optionally having 1 to 3 substituents selected from the group consist
- examples of the “halogen atom” include a fluorine atom, a chlorine atom, a bromine atom, and an iodine atom.
- examples of “C 1-15 alkoxy” include methoxy and ethoxy.
- examples of the “halo-C 1-15 alkoxy” include the above C 1-15 alkoxy substituted with one or more halogen atoms.
- the “cycloalkyl group” of the “cycloalkyl group which may have a substituent” represented by R 1 and R 2 is a cycloalkyl group having 3 to 7 carbon atoms (C 3-7 cycloalkyl group). Specific examples include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl and the like. Preferred is cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl, and more preferred is cyclopropyl or cyclobutyl.
- the substituent that the “cycloalkyl group optionally having substituent (s)” may have includes the “alkyl group optionally having substituent (s)” represented by R 1 and R 2. And the same groups as the substituents which may be used.
- the “alkyl group” of the “optionally substituted alkyl group” represented by R 3 is the “alkyl group” of the “optionally substituted alkyl group” represented by R 1 and R 2.
- the substituent which the said group may have, the same group as the substituent which the "alkyl group which may have a substituent" represented by R 1 and R 2 may have is the same. Can be mentioned.
- the “alkyl group” of the “alkyl group optionally having substituent (s)” represented by R 4 the “alkyl group” of the “alkyl group optionally having substituent (s)” represented by R 1 and R 2
- ⁇ group '' can be mentioned, and a C 1-6 alkyl group such as methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl or tert-butyl is preferable, and methyl is more preferable. It is done.
- the substituent which the said group may have the same group as the substituent which the "alkyl group which may have a substituent" represented by R 1 and R 2 may have is the same. Can be mentioned.
- the “aryl group” of the “aryl group optionally having substituent (s)” represented by R 4 means an aryl group having 6 to 14 carbon atoms (C 6-14 aryl group), for example, phenyl, naphthyl Or an ortho-fused bicyclic group having 8 to 10 ring atoms and at least one ring being an aromatic ring (for example, indenyl).
- substituents that the group may have include the same groups as the substituents that the “alkyl group that may have a substituent” represented by R 1 and R 2 may have. It is done.
- the “alkyl group” of the “alkyl group optionally having substituent (s)” represented by R 5 is the “alkyl group” of the “alkyl group optionally having substituent (s)” represented by R 1 and R 2.
- the same group as “group” can be mentioned, and an alkyl group having 1 to 6 carbon atoms (C 1-6 alkyl group) is preferable, and methyl is more preferable.
- the substituent which the said group may have the same group as the substituent which the "alkyl group which may have a substituent" represented by R 1 and R 2 may have is the same. Can be mentioned.
- halogen atom represented by Z
- Z examples include a fluorine atom, a bromine atom, a chlorine atom, and an iodine atom.
- a bromine atom and a chlorine atom are preferable.
- the “alkyl group” of the “optionally substituted alkyl group” represented by Z is the “alkyl group” of the “optionally substituted alkyl group” represented by R 1 and R 2. ”, Preferably an alkyl group having 1 to 6 carbon atoms (C 1-6 alkyl group), more preferably methyl. Moreover, as the substituent which the said group may have, the same group as the substituent which the "alkyl group which may have a substituent" represented by R 1 and R 2 may have is the same. Can be mentioned.
- the “cycloalkyl group” of the “cycloalkyl group optionally having substituents” represented by Z is the “cycloalkyl group optionally having substituents” represented by R 1 and R 2 .
- the same group as “cycloalkyl group” is mentioned, Preferably cyclohexyl is mentioned.
- the substituent which the said group may have the same group as the substituent which the "alkyl group which may have a substituent” represented by R 1 and R 2 may have is the same. Can be mentioned.
- the “aryl group” of the “aryl group optionally having substituent (s)” represented by Z means an aryl group having 6 to 14 carbon atoms (C 6-14 aryl group), such as phenyl, naphthyl, Or an ortho-fused bicyclic group having 8 to 10 ring atoms and at least one ring being an aromatic ring (for example, indenyl), etc., preferably phenyl or naphthyl, more preferably Is phenyl.
- Examples of the substituent that the aryl group may have include the substituents (1) to (1) that the “alkyl group that may have a substituent” represented by R 1 and R 2 may have.
- R 11 and R 12 , R 13 and R 14 are bonded to each other to form a carbon And forming a heterocycle optionally having heteroatoms;
- R 17 , R 18 and R 19 are each independently a hydrogen atom, a C 1-15 alkyl group, a C 3-7 cycloalkyl group, a C 6-14 aryl group, or a C 6-14 aryl-C 1-6 alkyl.
- the aryl moiety is “aryl” of the “aryl group optionally having substituent (s)” represented by Z
- the alkyl moiety is an alkyl group having 1 to 8 carbon atoms and may be linear or branched, such as benzyl, benzhydryl, 1-phenylethyl, 2-phenylethyl, phenylpropyl, phenylbutyl.
- C 6-14 aryl-C 1-8 alkyl such as phenylpentyl, phenylhexyl, naphthylmethyl, naphthylethyl and the like, with benzyl or naphthylmethyl being preferred.
- substituents that the group may have include the same groups as the substituent that the “aryl group that may have a substituent” represented by Z may have.
- the “arylalkenyl group” of the “arylalkenyl group optionally having substituents” represented by Z is the “aryl group” of the “arylgroup optionally having substituents” represented by Z.
- the “aryloxyalkyl group” of the “optionally substituted aryloxyalkyl group” represented by Z is the “aryl group” of the “optionally substituted aryl group” represented by Z "Means an alkyl group having 1 to 8 carbon atoms, which may be linear or branched, and bonded via an oxygen atom, specifically, for example, a (phenyloxy) methyl group, (1- Naphthyloxy) methyl group, (2-naphthyloxy) methyl group, 1- (phenyloxy) ethyl group, 2- (phenyloxy) ethyl group, 1- (1-naphthyloxy) ethyl group, 2- (1-naphthyl) Oxy) ethyl group, 1- (phenyloxy) propyl group, 2- (phenyloxy) propyl group, 3- (phenyloxy) propyl group, 4- (phenyloxy) butyl group, 5- (phenyl
- heteroaryl group of the “optionally substituted heteroaryl group” represented by Z is a 5- to 6-membered ring having carbon and 1 to 4 heteroatoms (oxygen, sulfur or nitrogen).
- Ortho-fused bicyclic heteroaryls having 8 to 10 ring atoms derived therefrom, in particular benz derivatives, or those derived by fusing propenylene, trimethylene or tetramethylene groups thereto, as well as their stable N-oxide and the like can be mentioned.
- heteroarylalkyl group of the “optionally substituted heteroarylalkyl group” represented by Z is the “heteroaryl group optionally substituted” whose heteroaryl moiety is represented by Z
- the alkyl moiety is an alkyl group having 1 to 3 carbon atoms and may be linear or branched.
- Examples of such groups include 2-pyrrolylmethyl, 2-pyridylmethyl, 3-pyridylmethyl, 4-pyridylmethyl, 2-thienylmethyl, 2- (2-pyridyl) ethyl, 2- (3-pyridyl) ethyl, And heteroaryl-C 1-3 alkyl groups such as 2- (4-pyridyl) ethyl, 3- (2-pyrrolyl) propyl and 4-imidazolylmethyl.
- R 1 is a C 1-15 alkyl group, more preferably a C 1-6 alkyl group, and most preferably a methyl group.
- R 2 is a C 1-15 alkyl group, more preferably a C 1-6 alkyl group, and most preferably a methyl group.
- R 3 are a hydrogen atom or a C 1-15 alkyl group, more preferably a hydrogen atom or a C 1-6 alkyl group, and most preferably a hydrogen atom or a tert-butyl group.
- R 4 include a hydrogen atom, a C 1-15 alkyl group, or a C 6-14 aryl group, and more preferably a hydrogen atom.
- a preferable example of m is an integer of 0 to 3, more preferably 0 or 1, and most preferably 0.
- Preferable examples of X are a bond, an oxygen atom or a sulfur atom, and more preferably a bond or an oxygen atom.
- a preferred example of Y is a carbonyl group or a group represented by —CH (OR 5 ) — (preferred examples of R 5 are a hydrogen atom or C 1-15 alkyl, more preferred Is a hydrogen atom or C 1-6 alkyl, most preferably a hydrogen atom or methyl.
- a halogen atom (2) an optionally substituted C 1-15 alkyl group, (3) an optionally substituted C 3-7 cycloalkyl group, (4) an optionally substituted C 6-14 aryl group, (5) an optionally substituted C 6-14 aryl-C 1-8 alkyl group, (6) an optionally substituted C 6-14 aryl-C 2-6 alkenyl group, (7) an optionally substituted C 6-14 aryloxy-C 1-8 alkyl group, (8) a heteroaryl group which may have a substituent or (9) a heteroaryl-C 1-3 alkyl group which may have a substituent, more preferably (1) a halogen atom, (2) a C 1-15 alkyl group, (3) a C 6-14 aryl group which may have a substituent or (4) a heteroaryl group which may have a substituent, more preferably (1) a halogen atom, (2) a C 1-6 alkyl group, (3) (i) C
- Z represents an aryl group which may have a substituent or a heteroaryl group which may have a substituent
- these groups are preferably represented by the following formulas (Za to Zn):
- R 6 , R 7 and R 8 are the same or different and (1) a hydrogen atom, (2) a halogen atom, (3) a C 1-6 alkyl group, (4) a halo-C 1-6 alkyl group, (5) (i) a halogen atom, (ii) hydroxy, (iii) Nitro, (iv) cyano, (v) amino, (vi) C 1-15 alkyl, (vii) halo-C 1-15 alkyl, (viii) a C 6-14 aryl group optionally having 1 to 3 substituents selected from the group consisting of C 1-15 alkoxy and (ix) halo-C 1-15 alkoxy; (6) (i) a halogen atom, (ii) hydroxy, (iii) Nitro, (iv) cyano, (v) amino, (vi) C 1-15 alkyl, (vii) halo-C 1-15 alkyl, (viii) a heteroaryl group optionally having 1 to 3
- R 9 represents a hydrogen atom, a halogen atom, a C 1-6 alkyl group, a C 3-7 cycloalkyl group, a halo-C 1-6 alkyl group, a C 6-14 aryl group, a halo-C 6-14 aryl group, Represents a heteroaryl group, a cyano group or a nitro group;
- R 10 represents a hydrogen atom, a C 1-6 alkyl group, a C 3-7 cycloalkyl group, a halo-C 1-6 alkyl group, a C 6-14 aryl group, a halo-C 6-14 aryl group, a C 6- 14 represents an aryl-C 1-6 alkyl group, a heteroaryl group or a heteroaryl-C 1-6 alkyl group;
- E 1 represents an oxygen atom, a sulfur atom or —NR 20 — (wherein R 20 represents a hydrogen atom, a C 1-6 alky
- C 1-6 alkyl group represented by R 6, R 7 and R 8 include the same groups as the C 1-6 alkyl group represented by R 1 and R 2.
- Examples of the halogen atom represented by R 6 , R 7 and R 8 include a fluorine atom, a bromine atom, a chlorine atom and an iodine atom.
- Examples of the halo-C 1-6 alkyl group represented by R 6 , R 7 and R 8 include groups obtained by substituting a C 1-6 alkyl group with a halogen atom.
- fluoromethyl, difluoromethyl, trifluoro Examples include methyl, chloromethyl, 2,2,2-trifluoroethyl, pentafluoroethyl and the like.
- Examples of the C 6-14 aryl group represented by R 6 , R 7 and R 8 include the same groups as the “aryl group” of the “aryl group optionally having substituents” represented by R 4. Is preferably a phenyl group.
- Examples of the heteroaryl group represented by R 6 , R 7 and R 8 include the same groups as the “heteroaryl group” of the “heteroaryl group optionally having substituent (s)” represented by Z. Pyridyl and pyrimidyl are preferable.
- Examples of the alkoxy group represented by R 6 , R 7 and R 8 include a C 1-15 alkoxy group, and specific examples include methoxy and ethoxy.
- Examples of the haloalkoxy group represented by R 6 , R 7 and R 8 include the above alkoxy groups substituted by a halogen atom, and examples thereof include trifluoromethoxy, 2,2,2-trifluoroethoxy, difluoromethoxy and the like. .
- the halogen atom represented by R 9 is preferably a chlorine atom or a bromine atom.
- the C 1-6 alkyl group represented by R 9 and R 10 include the same groups as the C 1-6 alkyl group represented by R 1 and R 2.
- the C 3-7 cycloalkyl group represented by R 9 and R 10 there may be mentioned the same groups as C 3-7 cycloalkyl group represented by R 1 and R 2, preferably, cyclohexyl.
- Examples of the halo-C 1-6 alkyl group represented by R 9 and R 10 include fluoromethyl, difluoromethyl, trifluoromethyl, chloromethyl, 2,2,2-trifluoroethyl, pentafluoroethyl and the like. .
- Examples of the C 6-14 aryl group represented by R 9 and R 10 include the same groups as the aryl group represented by R 4 , but a phenyl group is preferable.
- Preferred examples of the halo-C 6-14 aryl group represented by R 9 and R 10 include chlorophenyl and bromophenyl.
- Examples of the heteroaryl group represented by R 9 and R 10 include the same groups as the heteroaryl group represented by Z, and pyridyl and pyrimidyl are preferable.
- Examples of the C 6-14 aryl-C 1-6 alkyl group represented by R 10 include the same groups as the C 6-14 aryl-C 1-8 alkyl group represented by Z.
- Examples of the heteroaryl-C 1-6 alkyl group represented by R 10 include the same groups as the heteroaryl-C 1-3 alkyl group represented by Z.
- Examples of the C 1-6 alkyl group represented by R 11 , R 12 , R 13 , R 14 , R 15 and R 16 include the same groups as the C 1- alkyl group represented by R 1 and R 2 .
- Examples of the C 6-14 aryl group represented by R 11 , R 12 , R 13 , R 14 , R 15 and R 16 include the same groups as the aryl group represented by R 4 , but preferably a phenyl group. is there.
- Examples thereof include the same groups as those described above.
- Examples of the heteroaryl group represented by R 11 , R 12 , R 13 , R 14 , R 15 and R 16 include the same groups as the heteroaryl group represented by Z, preferably pyridyl and pyrimidyl.
- Examples of the heteroaryl-C 1-6 alkyl group represented by R 11 , R 12 , R 13 , R 14 , R 15 and R 16 include the same groups as the heteroarylalkyl group represented by Z.
- the heterocycle represented by R 11 and R 12 , R 13 and R 14 has 2 carbon atoms containing 1 to 3 heteroatoms selected from an oxygen atom, a sulfur atom and a nitrogen atom in addition to a carbon atom as a ring-constituting atom.
- non-aromatic heterocyclic groups such as azetidinyl, pyrrolidinyl, piperidino, piperazino, morpholino, 1,2,5,6-tetrahydropyridyl, thiomorpholino, oxothiomorpholino, dioxothiomorpholino, 3-azaspiro [5,5] undecyl, 1,3,8-triazaspiro [4,5] decyl and the like.
- C 1-6 alkyl group represented by R 17, R 18, R 19 and R 20 include the same groups as the C 1-6 alkyl group represented by R 1 and R 2.
- the C 6-14 aryl group represented by R 17, R 18, R 19 and R 20, there may be mentioned the same groups as C 6-14 aryl group represented by R 4, is preferably a phenyl group.
- the C 6-14 aryl -C 1-8 alkyl group represented by R 17, R 18, R 19 and R 20, the same groups as C 6-14 aryl -C 1-8 alkyl group represented by Z Can be mentioned.
- Examples of the heteroaryl group represented by R 17 , R 18 and R 19 include the same groups as the heteroaryl group represented by Z.
- Preferable are pyridyl and pyrimidyl.
- Examples of the heteroaryl-C 1-6 alkyl group represented by R 17 , R 18 , R 19 and R 20 include the same groups as the heteroaryl-C 1-3 alkyl group represented by Z.
- R 6 , R 7 , R 8 , R 9 and R 10 are particularly preferably a hydrogen atom, a C 1-6 alkyl group, a halo-C 1-6 alkyl group, a C 6-14 aryl group or a halo-C 6- 14 aryl group.
- Preferred examples of compound (I) include R 1 and R 2 are the same or different and each represents a C 1-15 alkyl group, R 3 represents a hydrogen atom or a C 1-15 alkyl group; R 4 represents a hydrogen atom; m represents 0; X represents a bond or an oxygen atom; Y represents a carbonyl group or a group represented by —CH (OR 5 ) — (wherein R 5 represents a hydrogen atom or a C 1-15 alkyl group);
- Z represents a halogen atom, a C 1-15 alkyl group, an optionally substituted C 6-14 aryl group or an optionally substituted heteroaryl group.
- the carboxylic acid derivatives shown shown.
- R 1 and R 2 are the same or different and each represents a C 1-6 alkyl group
- R 3 represents a hydrogen atom or a C 1-6 alkyl group
- R 4 represents a hydrogen atom
- m represents 0
- X represents a bond or an oxygen atom
- Y represents a carbonyl group or a group represented by —CH (OR 5 ) — (wherein R 5 represents a hydrogen atom or a C 1-6 alkyl group);
- Z is (1) a halogen atom, (2) a C 1-6 alkyl group, (3) (i) C 1-6 alkyl, (ii) halo-C 1-6 alkyl, (iii) C 6-14 aryl and (iv) may have 1 to 3 substituents selected from the group consisting of halo -C 6-14 aryl, C 6-14 aryl group or (Four) (i) C 1-6 alkyl, (ii) halo-C 1-6 alkyl, (ii
- R 1 , R 2 , R 3 , R 4 and m represent the same groups as described above, and Hal represents the same halogen atom as described above.
- R 1 , R 2 , R 3 , R 4 , m represent the same groups as described above. Or a pharmaceutically acceptable salt thereof, or a hydrate or solvate thereof.
- the pharmaceutically acceptable salts of compound (I) include all salts, but salts with inorganic acids such as hydrochloric acid or hydrobromic acid, salts with organic acids, salts with alkali metals, organic bases And salts with amino acids.
- compound (I) or a pharmaceutically acceptable salt thereof is solvated (for example, hydrate), metabolized in vivo and converted to compound (I) or a pharmaceutically acceptable salt thereof. All of the prodrugs or active metabolites of the compound (I) are also included.
- Compound (I) of the present invention can be synthesized, for example, by the following method, but the production method is not limited thereto.
- a compound represented by the general formula (I-1) wherein the Y moiety is a carbonyl group hereinafter referred to as compound (I-1)
- a compound represented by (I-2) hereinafter referred to as “compound”
- Compound (I-2) can be produced, for example, by the following method (Production Method 1).
- a compound represented by general formula (II-1) having a leaving group on the alkyl chain (hereinafter referred to as compound (II-1), etc .; the synthesis method will be described later) in the presence of a base (III-).
- the compound (I-1) which is an ether (thioether) compound can be obtained by reacting with the alcohol (thiol) derivative represented by 1) (hereinafter referred to as compound (III-1) etc.) (step) 1). Furthermore, this compound can be deesterified and converted into the carboxylic acid compound (I-2) (step 2).
- Compound (III-1) which is a raw material compound, is usually easily synthesized by a known method.
- R 3a represents an alkyl group
- X a represents an oxygen atom or a sulfur atom
- Z 1 represents an optionally substituted aryl. Group or a heteroaryl group which may be substituted
- Hal 1 represents a halogen atom.
- examples of the “alkyl group” represented by R 3a include the same groups as the “alkyl group” of the “alkyl group optionally having substituent (s)” represented by R 3 .
- Examples of the “optionally substituted aryl group” for Z 1 include the same groups as the “aryl group” for the “optionally substituted aryl group” for Z.
- the "optionally substituted heteroaryl group” represented by Z 1 include the same groups as "heteroaryl group” of the "optionally substituted heteroaryl group” represented by Z .
- Step 1 is usually performed in the presence of a base in a solvent that does not adversely influence the reaction.
- a base examples include alkali metal carbonates such as potassium carbonate, sodium carbonate and cesium carbonate, alkali metal alkoxides such as sodium methoxide, sodium ethoxide and potassium tertiary butoxide, potassium hydroxide, sodium hydroxide and lithium hydroxide.
- Metal hydrides such as alkali metal hydroxides such as potassium hydride and sodium hydride, triethylamine, N, N-diisopropylethylamine, N-methylmorpholine, pyridine, N, N-dimethylaniline, 4-dimethylaminopyridine, 1 , 8-Diazabicyclo [5.4.0] undec-7-ene and the like.
- the amount of the base used is preferably 1 to 5 molar equivalents relative to compound (II-1).
- the reaction can be carried out usually at a temperature of ⁇ 50 to 200 ° C., preferably ⁇ 10 to 100 ° C.
- Solvents that do not adversely affect the reaction include ethers such as diethyl ether, tetrahydrofuran and dioxane, halogenated hydrocarbons such as chloroform, dichloromethane and dichloroethane, hydrocarbons such as hexane, benzene and toluene, N, N-dimethyl Amides such as formamide and N-methyl-2-pyrrolidone, sulfoxides such as dimethyl sulfoxide, alcohols such as methanol and ethanol, ketones such as acetone, nitriles such as acetonitrile and propionitrile, water, etc. are used. . These solvents may be mixed and used at an appropriate ratio.
- ethers such as diethyl ether, tetrahydrofuran and dioxane
- halogenated hydrocarbons such as chloroform, dichloromethane and dichloroethane
- hydrocarbons such as hexane
- a phase transfer catalyst such as tetrabutylammonium iodide may be used.
- the amount of compound (III-1) to be used is generally 0.5 to 5 equivalents, preferably 0.9 to 1.1 equivalents, relative to compound (II-1).
- Step 2 is usually performed in a water-containing solvent in the presence of an acid or a base.
- the acid include formic acid, hydrochloric acid, sulfuric acid, acetic acid, hydrobromic acid, trifluoroacetic acid and the like.
- the base include alkali metal carbonates such as potassium carbonate and sodium carbonate, alkali metal alkoxides such as sodium methoxide and sodium ethoxide, and alkali metal hydroxides such as potassium hydroxide, sodium hydroxide and lithium hydroxide. It is done.
- the amount of acid or base used is usually an excess amount relative to compound (I-1).
- the amount of acid used is 2 to 100 molar equivalents relative to compound (I-1), and the amount of base used is 1.2 to 5 molar equivalents relative to compound (I-1).
- the water-containing solvent include alcohols such as methanol and ethanol, ethers such as tetrahydrofuran and dioxane, a mixed solvent of one or more solvents selected from dimethyl sulfoxide and acetone, and the like.
- R 3 is a tert-butyl group, acid decomposition can be performed in addition to the reaction in the water-containing solvent.
- Examples of the acid used for the acid decomposition include formic acid, hydrochloric acid, sulfuric acid, acetic acid, hydrobromic acid, trifluoroacetic acid, methanesulfonic acid, paratoluenesulfonic acid, and the like.
- the solvent may be mixed in an appropriate ratio.
- examples of such a solvent include halogenated hydrocarbons such as chloroform, dichloromethane and dichloroethane.
- the amount of the acid used is usually an excess amount relative to compound (I-1).
- the acid is used in an amount of 2 to 100 molar equivalents relative to compound (I-1).
- the reaction temperature is usually ⁇ 20 to 150 ° C., preferably ⁇ 10 to 100 ° C.
- the compound of general formula (I-1) can also be produced, for example, by the following method (Production Method 2).
- the ether (thioether) compound represented by the general formula (I-1) is a compound represented by the general formula (II-1) having a leaving group on the alkyl chain (the synthesis method will be described later) in the presence of a base. It can also be obtained by reacting with a metal alkoxide derivative represented by the general formula (III-2) (step 3).
- the compound (III-2) which is a raw material compound is usually easily synthesized by a known method.
- R 1 , R 2 , R 3a , R 4 , m, Hal 1 , X a , Z 1 are as defined above, and M represents a metal such as sodium, potassium, calcium, cesium, or silver. . ]
- Step 3 can usually be carried out in a solvent that does not adversely influence the reaction at ⁇ 50 to 200 ° C., preferably ⁇ 10 to 100 ° C.
- the solvent that does not adversely influence the reaction include alcohols such as methanol and ethanol, ketones such as acetone, nitriles such as acetonitrile and propionitrile, hydrocarbons such as benzene and toluene, water, and the like. These solvents may be mixed and used at an appropriate ratio.
- the amount of compound (III-2) to be used is generally 0.5 to 5 equivalents, preferably 1 to 2 equivalents, relative to compound (II-1).
- a compound represented by the formula (I-4) (hereinafter referred to as compound (I-4)) can be produced, for example, by the following method (Production Method 3).
- R 1 , R 2 , R 3a , R 4 , m, X, and Z 1 are as defined above.
- Step 4 is performed in the presence of a reducing agent in a solvent that does not adversely influence the reaction.
- a reducing agent for example, metal borohydride compounds such as sodium borohydride and lithium borohydride are used.
- the amount of the reducing agent to be used is preferably 1 to 5 molar equivalents relative to compound (I-1).
- the reaction temperature is usually ⁇ 50 to 150 ° C., preferably ⁇ 10 to 50 ° C.
- alcohols such as methanol and ethanol are used. These solvents may be mixed and used at an appropriate ratio.
- Step 5 can be carried out in the same manner as in step 2, except that compound (I-1) in step 2 is changed to compound (I-3).
- Z is an aryl group or heteroaryl group, and the aryl group or heteroaryl group has an aryl group or heteroaryl group on the ring of the general formula (I-6).
- the compounds represented by the following formulas (hereinafter referred to as compound (I-8)) and the compounds represented by general formula (I-9) (hereinafter referred to as compound (I-9)) are represented by production methods 1 to 3, respectively. In addition to the method shown, it can also be produced, for example, by the following method (production method 4).
- Z in the general formula (I) is an aryl group or a heteroaryl group, and has a leaving group such as a halogen atom or a trifluoromethanesulfonyloxy group on the ring of the aryl group or heteroaryl group.
- 5) hereinafter described as compound (I-5)
- a boron compound represented by general formula (III-3) hereinafter described as compound (III-3)
- general formula (III -4) is reacted with a tin compound (hereinafter referred to as compound (III-4)) in the presence of a metal catalyst to introduce an aryl group or heteroaryl group compound (I-6) ) Can be obtained (step 6).
- this compound can be deesterified and converted into the carboxylic acid compound (I-7) (step 7). Further, it can be converted into the compound (I-8) which is an alcohol form in the same manner as in Production Method 3 (Step 8), and further deesterified to the compound (I-9) which is a carboxylic acid form. Can be converted (step 9).
- the starting compounds (III-3) and (III-4) are usually easily synthesized by known methods.
- R 1 , R 2 , R 3a , R 4 , X, m are as defined above, Z 2 represents an aryl group or a heteroaryl group, and Hal 2 represents a halogen atom or a trifluoromethanesulfonyloxy group.
- R a represents an aryl group or a heteroaryl group
- R b represents a hydrogen atom or an alkyl group
- two R b together represent an orthophenylene group, an ethylene group, 1,1,2,2 -Forms a tetramethylethylene group or a 1,3-propylene group
- R c represents an alkyl group.
- examples of the “aryl group” represented by Z 2 and R a include the same groups as the “aryl group” of the “aryl group optionally having substituent (s)” represented by Z.
- examples of the “heteroaryl group” represented by Z 2 and R a include the same groups as the “heteroaryl group” of the “heteroaryl group optionally having substituent (s)” represented by Z.
- Examples of the “alkyl group” represented by R b and R c include the same groups as the “alkyl group” of the “alkyl group optionally having substituent (s)” represented by R 1 and R 2 .
- Step 6 is usually performed in the presence of a metal catalyst in a solvent that does not adversely influence the reaction.
- a metal catalyst include a zero-valent palladium catalyst, a divalent palladium catalyst, and a zero-valent nickel catalyst.
- the zero-valent palladium catalyst include tetrakis (triphenylphosphine) palladium and tris (dibenzylideneacetone) dipalladium
- examples of the divalent palladium catalyst include palladium acetate and dichlorobis (triphenylphosphine) palladium.
- the zero-valent nickel catalyst include 1,1′-bis (diphenylphosphino) ferrocene nickel.
- monodentate ligands such as triphenylphosphine and tris (o-tolyl) phosphine
- bidentate ligands such as diphenylphosphinopropane and diphenylphosphinobutane
- the base include alkali metal hydrogen carbonates such as sodium hydrogen carbonate, alkali metal carbonates such as sodium carbonate and potassium carbonate, and alkali metal phosphates such as tripotassium phosphate.
- alkali metal hydrogen carbonates such as sodium hydrogen carbonate
- alkali metal carbonates such as sodium carbonate and potassium carbonate
- alkali metal phosphates such as tripotassium phosphate.
- the amount of the metal catalyst to be used is, for example, 0.01 to 1 molar equivalent, preferably 0.05 to 0.5 molar equivalent, relative to compound (I-5).
- the amount of the base to be used is, for example, 1 to 20 molar equivalents, preferably 1 to 10 molar equivalents, relative to compound (I-5).
- the reaction temperature is usually 0 ° C. to the reflux temperature of the solvent.
- Solvents that do not adversely affect the reaction include ethers such as tetrahydrofuran and dioxane, aromatic hydrocarbons such as benzene and toluene, amides such as N, N-dimethylformamide and N-methyl-2-pyrrolidone, methanol, Alcohols such as ethanol, water and the like are used. These solvents may be mixed and used at an appropriate ratio. In the case of the reaction with compound (III-4), it is preferably carried out in a non-aqueous solvent.
- the amount of compound (III-3) or compound (III-4) to be used is, for example, 1 to 5 molar equivalents, preferably 1 to 3 molar equivalents, relative to compound (I-5).
- Steps 7 and 9 are performed in the same manner as in Step 2, except that Compound (I-1) in Step 2 of Production Method 1 is changed to Compound (I-6) and Compound (I-8), respectively. Can do. Step 8 can be performed according to a method similar to that of step 4 of manufacturing method 3.
- the Y moiety is represented by the general formula (I-10) in which —CH (OR 5 ′ ) — (R 5 ′ represents an alkyl group having 1 to 6 carbon atoms).
- a compound (hereinafter referred to as compound (I-10)) and a compound represented by general formula (I-11) (hereinafter referred to as compound (I-11)) can be produced, for example, by the following method. (Manufacturing method 5).
- Compound (I-10) can be obtained by alkylating the hydroxyl group of compound (I-3) obtained by production method 3 (step 10). Furthermore, compound (I-11) can be produced by deesterification of this compound (step 11).
- R 5 ′ represents an alkyl group
- R 1 , R 2 , R 3a , R 4 , X, m, and Z 1 are as defined above.
- Examples of the “alkyl group” represented by R 5 ′ include the same groups as the “alkyl group” of the “alkyl group optionally having substituent (s)” represented by R 1 and R 2 .
- Step 10 is usually performed by allowing an alkylating agent to act in a solvent that does not adversely affect the reaction in the presence of a base.
- a base metal hydrides such as sodium hydride and potassium hydride, and alkali metal alkoxides such as potassium tertiary butyl oxide are used.
- the amount of the base to be used is, for example, 0.5 to 10 molar equivalents, preferably 1 to 2 molar equivalents, relative to compound (I-3).
- the alkylating agent include alkyl halides such as methyl iodide and ethyl bromide, and alkyl sulfonic acid esters such as dimethyl sulfate.
- the amount of the alkylating agent to be used is, for example, 0.5 to 10 molar equivalents, preferably 1 to 3 molar equivalents, relative to compound (I-3).
- the reaction is usually carried out in the range of ⁇ 50 ° C. to 200 ° C., preferably 0 ° C. to 100 ° C.
- the solvent that does not adversely influence the reaction include tetrahydrofuran, dimethylformamide, N-methylpyrrolidone and the like. These solvents may be mixed and used at an appropriate ratio.
- Step 11 can be carried out in the same manner as Step 2, except that the compound (I-1) in Step 2 is changed to the compound (I-10).
- the Y moiety is —CH (OH) — and is an optically active compound represented by general formula (I-14) (hereinafter referred to as compound (I-14)).
- a compound represented by the general formula (I-15) (hereinafter referred to as compound (I-15)) can be produced, for example, by the following method (Production Methods 6 and 7).
- step 12 known conditions are selected according to the optically active carboxylic acid derivative to be used.
- an acid chloride such as (+)- ⁇ -methoxy- ⁇ -trifluoromethylphenylacetyl chloride
- a base in a solvent that does not adversely influence the reaction.
- an organic base such as 4-dimethylaminopyridine, pyridine, triethylamine or the like is used.
- the amount of the base is usually 0.1 to 10 molar equivalents relative to compound (I-3).
- the reaction temperature is usually ⁇ 20 ° C. to 100 ° C., preferably 0 ° C. to 50 ° C.
- Solvents that do not adversely affect the reaction include ethers such as diethyl ether, tetrahydrofuran and dioxane, halogenated hydrocarbons such as chloroform, dichloromethane and dichloroethane, hydrocarbons such as hexane, benzene and toluene, Pyridine, which is a base, can also be used as a solvent. These solvents may be mixed and used at an appropriate ratio.
- the amount of the derivative to be used is generally 0.1 to 5 molar equivalents, preferably 0.5 to 2 molar equivalents, relative to compound (I-3).
- step 13 can be performed by a purification method in ordinary organic synthesis such as crystallization and column chromatography, and a combination thereof, according to the property of the compound (I-12) which is a diastereo mixture.
- Step 14 and Step 15 can be carried out in the same manner as in Step 2, except that compound (I-1) in step 2 is changed to compound (I-13) and / or compound (I-14). Step 14 and step 15 may be performed in reverse order or simultaneously.
- Compound (I-14) which is an optically active alcohol can also be obtained by subjecting compound (I-1) obtained in Step 1 of Production Method 1 to asymmetric reduction (Step 16). Furthermore, compound (I-14) can be deesterified and converted to compound (I-15) which is a carboxylic acid form (step 17).
- R 1 , R 2 , R 3a , R 4 , X a , Z 1 , m are as defined above.
- Step 16 is described in, for example, non-patent literature (4th edition, Experimental Chemistry Course 26, Organic Synthesis VIII 23 to 68 pages, 5th edition, Experimental Chemistry Course 19 Synthesis of Organic Compounds VII pages 65 to 170) edited by The Chemical Society of Japan. It can be performed by a known method for asymmetric reduction of a carbonyl group.
- a reducing agent and an asymmetric ligand can be combined in a solvent that does not adversely influence the reaction.
- the reducing agent borane complexes such as borane-tetrahydrofuran complex and borane-dimethyl sulfide complex are used.
- the amount of the reducing agent to be used is preferably 1 to 5 molar equivalents relative to compound (I-1).
- Examples of the asymmetric ligand include (S)-( ⁇ )-2-methyl-CBS-oxazaborolidine, and the amount used is 0.001 to 10 molar equivalents, preferably 0.01 to 0.5 molar equivalents.
- the reaction temperature is usually ⁇ 50 to 150 ° C., preferably ⁇ 10 to 50 ° C.
- Examples of the solvent that does not adversely influence the reaction include ethers such as diethyl ether, tetrahydrofuran and dioxane, halogenated hydrocarbons such as chloroform, dichloromethane and dichloroethane, and hydrocarbons such as hexane, benzene and toluene. These solvents may be mixed and used at an appropriate ratio.
- Step 17 can be carried out in the same manner as in step 2, except that compound (I-1) in step 2 is changed to compound (I-14).
- the compound (I-15) obtained by the production method 6 or 7 is a known method in organic synthesis, for example, purification by chiral column chromatography, or optically active such as (S) or (R) -phenylethylamine. Optical purity can be increased by performing chlorination and crystallization with an organic amine.
- the compound (II-1) used in the above production method is, for example, a compound represented by general formula (V) having a thiol group shown below (hereinafter referred to as compound (V)) as a starting material. It can be manufactured by the method shown in the manufacturing method 8 or 9. Compound (V) can be produced according to the method described in International Publication No. 2006/049232.
- the haloketone (II-1) can be obtained by halomethylation of the carboxylic acid compound (V). (Step 18)
- Step 18 is a known method, for example, a method via diazo ketone described in non-patent literature (J. Org. Chem. 20 (1955), 38.); non-patent literature (Tetrahedron Lett. 42 (2001), 5887 ), A method in which dihalomethane is allowed to act on an ester obtained from a carboxylic acid in the presence of a base such as lithium diisoproamide; described in non-patent literature (J. Chem. Soc. Chem. Commun.
- the reaction of the metal enolate prepared from haloacetic acid or a salt thereof is carried out by reacting haloacetic acid or a salt thereof with a lower alkyl ester such as methyl or ethyl ester which can be easily synthesized from compound (V) by a method known in the literature.
- the reaction is usually carried out in a solvent that does not affect the reaction in the range of ⁇ 50 ° C. to 100 ° C., preferably ⁇ 10 ° C. to 50 ° C.
- solvent that does not affect the reaction include ethers such as tetrahydrofuran and diethyl ether.
- a compound represented by general formula (VI) (hereinafter referred to as compound (VI)) is produced from compound (V) (step 19), and halogenated using this to produce haloketone (II-1) ) Can be manufactured (step 20).
- Step 19 can be performed, for example, by reacting a compound (V) which is a carboxylic acid or an appropriate derivative thereof with an organometallic reagent.
- organometallic reagents include hydroxamic acid esters that can be synthesized by known methods.
- organometallic reagents include Grignard reagents such as methylmagnesium bromide and alkyllithium reagents such as methyllithium.
- the amount of the organometallic reagent to be used is generally 1 to 10 molar equivalents, preferably 3 to 5 molar equivalents, relative to compound (V) or an appropriate derivative thereof.
- the reaction can be carried out usually in a range of ⁇ 50 ° C. to 100 ° C., preferably ⁇ 20 ° C. to 30 ° C., in a solvent that does not adversely influence the reaction.
- the solvent that does not adversely influence the reaction include ethers such as tetrahydrofuran and diethyl ether
- Step 20 is carried out in the presence of a halogenating agent such as phenyltrimethylammonium tribromide in a solvent that does not adversely influence the reaction, usually in the range of ⁇ 50 ° C. to 100 ° C., preferably ⁇ 10 ° C. to 40 ° C. Can do.
- a solvent that does not adversely influence the reaction include ethers such as tetrahydrofuran and diethyl ether, and halogenated hydrocarbons such as chloroform and carbon tetrachloride.
- the amount of the halogenating agent to be used is generally 0.5 to 5 molar equivalents, preferably 0.9 to 2 molar equivalents, relative to the compound.
- Z represents a cycloalkyl group, an arylalkyl group, an aryloxyalkyl group, or a heteroaryl group, it can be similarly produced by following the above method.
- the compound (I) of the present invention thus produced can be of any purity by appropriately applying known separation and purification means such as concentration, extraction, chromatography, reprecipitation, recrystallization and the like. Can be collected as In addition, the compound (I) thus obtained may be prepared by using an inorganic acid such as hydrochloric acid or hydrobromic acid, an organic acid such as trifluoroacetic acid, acetic acid, methanesulfonic acid, or benzenesulfonic acid, sodium, potassium, calcium, etc. These salts can be obtained by treating with an alkali metal, an organic base such as dicyclohexylamine, or an amino acid such as lysine or arginine.
- an inorganic acid such as hydrochloric acid or hydrobromic acid
- an organic acid such as trifluoroacetic acid, acetic acid, methanesulfonic acid, or benzenesulfonic acid, sodium, potassium, calcium, etc.
- These salts can be obtained by treating with
- the compound (I) of the present invention is effective from the viewpoint of prevention and / or treatment of hyperlipidemia, arteriosclerosis and ischemic heart disease, and is a highly safe preventive and / or therapeutic agent for hyperlipidemia. As useful. Furthermore, the compound (I) of the present invention is also useful as a prophylactic and / or therapeutic agent for hyperlipidemia associated with diabetes.
- Hyperlipidemia associated with diabetes refers to a case in which a diabetic patient develops hyperlipidemia and is sometimes referred to as diabetic hyperlipidemia.
- a pathological condition in which a diabetic patient has developed hyperlipidemia means that a TG value, an LDL-C value, an HDL-C value, etc.
- the medicament of the present invention can be applied to these disease states for therapeutic purposes.
- the medicament of the present invention is applied for the purpose of treatment or prevention It is possible.
- a patient exhibiting hyperlipidemia associated with diabetes refers to a TG value, an LDL-C value, an HDL-C value, etc., even if the blood glucose level is improved by treatment of diabetes. It refers to patients who do not show normal values, and the medicament of the present invention can be administered to these patients.
- the WHO classification that classifies hyperlipidemia by the lipoprotein phenotype is known.
- the phenotypes in which triglycerides are elevated include type I hyperlipidemia, type IIb hyperlipidemia, type III hyperlipidemia, type IV hyperlipidemia, type V hyperlipidemia, etc.
- the medicament of the present invention can also be applied to patients belonging to other classifications and diagnosed with hyperlipidemia associated with diabetes.
- the TG value, LDL-C value, HDL-C value, etc. are within the normal value range. It is possible to apply in.
- the compound (I) of the present invention can also be used as a preventive and / or therapeutic agent for diabetes.
- diabetes refers to a case where the fasting blood glucose level is 126 mg / dL or more, or the 75 g glucose tolerance test 2 hour value is 200 mg / dL or more.
- it is considered as diabetes also when a blood glucose level is 200 mg / dL or more as needed.
- the compound (I) of the present invention can be administered to the same subject simultaneously with other antihyperlipidemic agents and the like, and can be administered to the same subject with a time lag.
- antihyperlipidemic agents include statins that are cholesterol synthetase inhibitors, squalene synthetases inhibitors, and fibrate compounds that have a triglyceride-lowering action.
- statins that are cholesterol synthetase inhibitors, squalene synthetases inhibitors, and fibrate compounds that have a triglyceride-lowering action.
- the compounding ratio can be appropriately selected depending on the administration subject, age and weight of the administration subject, symptoms, administration time, dosage form, administration method, combination and the like.
- the preferred compound of the present invention in particular, the compound of Example 12 is not involved in metabolism by CYP, it can be used in combination with a drug involved in metabolism by CYP (for example, fluvastatin), and is highly safe. It can be an excellent preventive or therapeutic agent for hyperlipidemia.
- a drug involved in metabolism by CYP for example, fluvastatin
- the compound (I) and the acid addition salt thereof of the present invention are used as the above-mentioned medicaments, they are mixed with themselves or with an appropriate pharmaceutically acceptable carrier to form powders, granules, tablets, capsules, injections, etc. And can be administered orally or parenterally.
- Pharmaceutically acceptable carriers include diluents, binders (syrup, gum arabic, gelatin, sorbit, tragacanth, polyvinylpyrrolidone), excipients (lactose, sucrose, corn starch, potassium phosphate, sorbit, glycine), A lubricant (magnesium stearate, talc, polyethylene glycol, silica), a disintegrant (potato starch), a wetting agent (sodium lauryl sulfate) and the like can be mentioned. In the above preparation, an effective amount of compound (I) or a pharmaceutically acceptable salt thereof is blended.
- the dose of the compound (I) of the present invention or a pharmaceutically acceptable salt thereof varies depending on the administration route, target disease, patient symptom, body weight or age, and the compound to be used, and may be appropriately set according to the purpose of administration. it can.
- TMS tetramethylsilane
- ppm parts per million
- the coupling constant is expressed in hertz (Hz), and the obvious multiplicity is s (singlet), d (doublet), t (triplet), q (quartet), quint (quintet), m (multiplet), dd (doublet) Of doublets), td (triplet of doublets), and brs (broad singlet).
- the result of mass spectrometry showed a value of (M + H) + by high performance liquid chromatography mass spectrometry (electrospray ionization method).
- the solvent was distilled off, and the residue was dissolved again in 700 mL of ethyl acetate, washed successively with dilute hydrochloric acid (about 0.2 mol / L), saturated aqueous sodium hydrogen carbonate solution and saturated aqueous sodium chloride solution, each 300 mL, and dried over anhydrous sodium sulfate.
- the solid obtained by distilling off the solvent was washed with a mixed solvent of hexane and ethyl acetate (10: 1, about 500 mL), and the solid was collected by filtration.
- the organic layer was washed twice with 300 mL of a 1 mol / L aqueous sodium hydroxide solution and further twice with 200 mL of a saturated aqueous sodium chloride solution and then dried over anhydrous sodium sulfate, and the solvent was distilled off.
- Example 7-1 2-[(4- ⁇ [(5-Bromopyridin-2-yl) oxy] -acetyl ⁇ -1,3-thiazol-2-yl) thio] -2-methylpropionic acid tert-butyl ester
- N, O-dimethylhydroxylamine hydrochloride was suspended in 50 mL of tetrahydrofuran, and 50 mL of 20% potassium carbonate aqueous solution was added to form a free amine, followed by liquid separation, and the organic layer was dried over sodium sulfate.
- the solution from which the desiccant was filtered off was added to the previous dimethylformamide reaction solution and stirred overnight at room temperature.
- 500 mL of water was added to the reaction mixture and stirred, followed by extraction twice with 500 mL of ethyl acetate.
- Example 10-1 2-[(4- ⁇ [(4′-Fluorobiphenyl-4-yl) oxy] acetyl ⁇ -1,3-thiazol-2-yl) thio] -2-methylpropionic acid tert-butyl ester
- Example 9 10.462 g of the obtained bromoketone compound was dissolved in 300 mL of acetone, 5.17 g of 4′-fluorobiphenyl-4-ol and 3.80 g of potassium carbonate were added, and the mixture was heated to reflux for 6 hours and 20 minutes.
- Example 10-2 2-[(4- ⁇ (1S) -2-[(4′-fluorobiphenyl-4-yl) oxy] -1-hydroxyethyl ⁇ -1,3-thiazol-2-yl) thio] -2-methyl
- Example 2 Propionic acid tert-butyl ester (S)-( ⁇ )-2-methyl-CBS-oxaborozine 410 mg and borane-dimethylsulfide complex (1 mol / L methylene chloride solution) 11.84 mL were dissolved in 30 mL of methylene chloride.
- Example 10-3 2-[(4- ⁇ (1S) -2-[(4′-fluorobiphenyl-4-yl) oxy] -1-hydroxyethyl ⁇ -1,3-thiazol-2-yl) thio] -2-methyl Propionic acid 2-[(4- ⁇ (1S) -2-[(4′-fluorobiphenyl-4-yl) oxy] -1-hydroxyethyl ⁇ -1,3-thiazole obtained in Example 10-2 -2-yl) thio] -2-methylpropionic acid tert-butyl ester (904 mg) was dissolved in dioxane (5 mL), concentrated hydrochloric acid (0.5 mL) was added, and the mixture was stirred at an oil bath temperature of 95 ° C.
- Precipitated solid (isomer mixture ratio 73.46: 26.54.
- the precipitated solid was collected by filtration to obtain 3.137 g of a salt (isomer ratio 99.79: 0.21).
- the salt obtained in the above dividing step was dissolved in a mixed solvent of 30 mL of water and 10 mL of ethanol, and the pH was adjusted to about 1 with 1 mol / L hydrochloric acid water. After evaporating the solvent, the mixture was extracted with 100 mL of ethyl acetate, washed with saturated brine, and dried over anhydrous sodium sulfate.
- Example 11 2-[(4- ⁇ (1R) -2-[(4′-fluorobiphenyl-4-yl) oxy] -1-hydroxyethyl ⁇ -1,3-thiazol-2-yl) thio] -2-methyl Propionic acid (S)-( ⁇ )-2-Methyl-CBS-oxaborozine is used instead of (R)-(+)-2-methyl-CBS-oxaborozine to carry out the same reaction as in Example 10. Gave 791 mg of the title compound.
- Example 12-1 1- ⁇ 2-[(2-tert-butoxy-1,1-dimethyl-2-oxoethyl) thio] -1,3-thiazozol-4-yl ⁇ -2-[(4′-fluorobiphenyl-4-yl ) Oxy] ethyl (2R) -3,3,3-trifluoro-2-methoxy-2-phenylpropionic acid
- Crystal B was found to have an absolute configuration of (1R) by X-ray crystal structure analysis. Therefore, the absolute configuration of crystal A was determined as (1S) isomer.
- Example 12-2 2-[(4- ⁇ (1S) -2-[(4′-fluorobiphenyl-4-yl) oxy] -1-hydroxyethyl ⁇ -1,3-thiazol-2-yl) thio] -2-methyl Propionic acid 900 mg of the crystal A obtained in Example 12-1 was dissolved in 10 mL of tetrahydrofuran, 1.9 mL of 1 mol / L sodium hydroxide aqueous solution was added, and the mixture was heated to reflux for 2 hours and 10 minutes. Since it was found by TLC that the acyl substance of the raw material remained, 0.6 mL of an aqueous sodium hydroxide solution was added, and the mixture was further heated to reflux for 7 hours 30 minutes.
- Example 13 2-[(4- ⁇ (1R) -2-[(4′-fluorobiphenyl-4-yl) oxy] -1-hydroxyethyl ⁇ -1,3-thiazol-2-yl) thio] -2-methyl Propionic acid Using 800 mg of the crystals B obtained in Example 12-1, in the same manner as in Example 12-2, 310 mg of the title compound was obtained.
- the compound of the present invention has a strong transcriptional activity on human PPAR ⁇ . From the above, it was revealed that the compound of the present invention has a human PPAR ⁇ inhibitory action. Further, as shown in the above table, in the experimental example, the transcriptional activation action of Compound A is 10.41 nmol / l, and the preferred compound of the present invention, in particular, the compound of Example 12 shows three times or more stronger activity. It was.
- the compound of the present invention has an excellent blood TG lowering action.
- the compound of Example 12 showed a 15.1% TG lowering effect when administered at 0.01 mg / kg, whereas Compound A showed almost no TG lowering action at the same dose (TG lowering action). : 0.7%). Therefore, it was found that the compound of Experimental Example 12 exhibited an excellent TG lowering action from a low dose as compared with Compound A.
- the rate of decrease is the value obtained by subtracting the mean blood TG (or mean blood TC) in the drug administration group from the mean blood triglyceride (TG) (or mean blood total cholesterol (TC)) in the vehicle administration group It calculated by calculating
- the results are shown in Table 3.
- reaction solution for investigating an inhibitor [ 14 C-labeled test compound (0.2 ⁇ mol / L and 2 ⁇ mol / L), inhibitor solution (Sulphaphenazole) (10 ⁇ mol / L), human liver microsome (0.5 mg) protein / mL), EDTA (0.05 mmol / L) and Na-K phosphate buffer (pH 7.4, 0.1 mol / L)] and preincubating for 5 minutes at 37 ° C. The solution was added to start the reaction.
- reaction was stopped by adding 3 times the amount of ethanol as the reaction solution.
- a predetermined amount of unlabeled metabolite mixed solution was added to this reaction solution, stirred (about 5 minutes), centrifuged (4 ° C., 3000 rpm, 10 minutes), and the supernatant was collected.
- Three times the amount of ethanol as the reaction solution was added to the residue, stirred (about 5 minutes), and then centrifuged (4 ° C., 3000 rpm, 10 minutes). The supernatant was collected, combined with the previously collected supernatant, and the solvent was distilled off at about 40 ° C. under a nitrogen stream.
- ADVANTAGE OF THE INVENTION it can provide the compound which has a PPAR (alpha) agonist effect and is useful as a highly safe preventive and / or therapeutic agent for hyperlipidemia. Further, according to the present invention, an intermediate useful for synthesizing the above compound can be provided. This application is based on Japanese Patent Application No. 2008-306803 filed in Japan (filing date: December 1, 2008), the contents of which are incorporated in full herein.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Diabetes (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Description
フィブラート系薬剤はPPARαを活性化することにより、脂肪酸の代謝に関連する遺伝子(アシルCoA合成酵素、リポ蛋白リパーゼ、脂肪酸輸送蛋白など)や中性脂肪(TG)およびコレステロール代謝に関与するアポリポ蛋白(AI、AII、AV、CIII)遺伝子の発現を調節し、TGならびにLDLコレステロールを低下させ、HDLコレステロールを増加させるため高脂血症治療薬として高い有効性を示すことが知られている。
[1]下記式(I)
R1およびR2は、同一または異なって、水素原子もしくは置換基を有していてもよいアルキル基を示すか、またはR1およびR2は相互に結合して、置換基を有していてもよいシクロアルキル基を形成し;
R3は、水素原子または置換基を有していてもよいアルキル基を示し;
R4は、水素原子、置換基を有していてもよいアルキル基または置換基を有していてもよいアリール基を示し;
mは、0~3の整数を示し;
Xは、結合、酸素原子または硫黄原子を示し;
Yは、カルボニル基または-CH(OR5)-(式中、R5は、水素原子または置換基を有していてもよいアルキル基を示す)で表される基を示し;
Zは、
ハロゲン原子、
置換基を有していてもよいアルキル基、
置換基を有していてもよいシクロアルキル基、
置換基を有していてもよいアリール基、
置換基を有していてもよいアリールアルキル基、
置換基を有していてもよいアリールアルケニル基、
置換基を有していてもよいアリールオキシアルキル基、
置換基を有していてもよいヘテロアリール基または
置換基を有していてもよいヘテロアリールアルキル基を示す。〕で表されるチアゾール環を含むカルボン酸誘導体若しくはその医薬上許容される塩またはそれらの水和物若しくは溶媒和物;
[2]下記式(I’)
[3]R1およびR2が、同一または異なって、C1-15アルキル基を示し、
R3が、水素原子またはC1-15アルキル基を示し;
R4が、水素原子を示し;
mが、0を示し;
Xが、結合または酸素原子を示し;
Yが、カルボニル基または-CH(OR5)-(式中、R5は、水素原子またはC1-15アルキル基を示す)で表される基を示し;
Zが、ハロゲン原子、C1-15アルキル基、置換基を有していてもよいC6-14アリール基または置換基を有していてもよいヘテロアリール基を示す、
[1]または[2]に記載のカルボン酸誘導体若しくはその医薬上許容される塩またはそれらの水和物若しくは溶媒和物;
[4]R1およびR2が、同一または異なって、C1-6アルキル基を示し、
R3が、水素原子またはC1-6アルキル基を示し;
R4が、水素原子を示し;
mが、0を示し;
Xが、結合または酸素原子を示し;
Yが、カルボニル基または-CH(OR5)-(式中、R5は、水素原子またはC1-6アルキル基を示す)で表される基を示し;
Zが、
(1) ハロゲン原子、
(2) C1-6アルキル基、
(3)
(i) C1-6アルキル、
(ii) ハロ-C1-6アルキル、
(iii) C6-14アリールおよび
(iv) ハロ-C6-14アリール
からなる群から選択される1~3個の置換基を有していてもよい、C6-14アリール基または
(4)
(i) C1-6アルキル、
(ii) ハロ-C1-6アルキル、
(iii) C6-14アリールおよび
(iv) ハロ-C6-14アリール
からなる群から選択される1~3個の置換基を有していてもよい、ヘテロアリール基を示す、
[1]または[2]に記載のカルボン酸誘導体若しくはその医薬上許容される塩またはそれらの水和物若しくは溶媒和物;
[5]式(I)または式(I’)中、
Zにおける置換基を有していてもよいアリール基または置換基を有していてもよいヘテロアリール基が、下記式(Za~Zn)
R6、R7、R8、R9およびR10は、同一または異なって、水素原子、C1-6アルキル基、ハロ-C1-6アルキル基、C6-14アリール基またはハロ-C6-14アリール基を示し、
E1は、酸素原子、硫黄原子または-NR20-(式中、R20は水素原子、C1-6アルキル基、C3-7シクロアルキル基、C6-14アリール基、C6-14アリール-C1-6アルキル基またはヘテロアリール-C1-6アルキル基を示す)。〕
からなる群から選択される置換基で表される、[1]~[3]のいずれか一に記載のカルボン酸誘導体若しくはその医薬上許容される塩またはそれらの水和物若しくは溶媒和物;
[6]2-[(4-{[(4’-フルオロビフェニル-4-イル)オキシ]アセチル}-1,3-チアゾール-2-イル)チオ]-2-メチルプロピオン酸;
2-[(4-{2-[(4’-フルオロビフェニル-4-イル)オキシ]-1-ヒドロキシエチル}-1,3-チアゾール-2-イル)チオ]-2-メチルプロピオン酸;
2-[(4-{[(4’-クロロビフェニル-4-イル)オキシ]アセチル}-1,3-チアゾール-2-イル)チオ]-2-メチルプロピオン酸;
2-[(4-{2-[(4’-クロロビフェニル-4-イル)オキシ]-1-ヒドロキシエチル}-1,3-チアゾール-2-イル)チオ]-2-メチルプロピオン酸;
2-[(4-{2-[(4’-フルオロビフェニル-4-イル)オキシ]-1-メトキシエチル}-1,3-チアゾール-2-イル)チオ]-2-メチルプロピオン酸;
2-{[4-(2-{[5-(4-フルオロフェニル)ピリジン-2-イル]オキシ}-1-ヒドロキシエチル)-1,3-チアゾール-2-イル]チオ}-2-メチルプロピオン酸;
2-[(4-{(1S)-2-[(4’―フルオロビフェニル-4-イル)オキシ]-1-ヒドロキシエチル}-1,3-チアゾール-2-イル)チオ]-2-メチルプロピオン酸;
または
2-[(4-{(1R)-2-[(4’―フルオロビフェニル-4-イル)オキシ]-1-ヒドロキシエチル}-1,3-チアゾール-2-イル)チオ]-2-メチルプロピオン酸;
であるカルボン酸またはその誘導体若しくはその医薬上許容される塩またはそれらの水和物若しくは溶媒和物;
[7][1]~[6]のいずれか一に記載のカルボン酸誘導体若しくはその医薬上許容される塩またはそれらの水和物若しくは溶媒和物を有効成分として含有する、高脂血症、糖尿病に合併した高脂血症、動脈硬化症、虚血性心疾患および糖尿病から選ばれる疾患の予防及び/又は治療薬;
[8][1]~[6]のいずれか一に記載のカルボン酸誘導体若しくはその医薬上許容される塩またはそれらの水和物若しくは溶媒和物の、高脂血症、糖尿病に合併した高脂血症、動脈硬化症、虚血性心疾患および糖尿病から選ばれる疾患の予防及び/又は治療用医薬の製造のための使用;
[9][1]~[6]のいずれか一に記載のカルボン酸誘導体若しくはその医薬上許容される塩またはそれらの水和物若しくは溶媒和物、および医薬上許容される担体からなる医薬組成物;
[10][1]~[6]のいずれか一に記載のカルボン酸誘導体若しくはその医薬上許容される塩またはそれらの水和物若しくは溶媒和物を、それを必要とする対象に投与することを特徴とする、高脂血症、糖尿病に合併した高脂血症、動脈硬化症、虚血性心疾患および糖尿病から選ばれる疾患の予防及び/又は治療方法;
[11]高脂血症、糖尿病に合併した高脂血症、動脈硬化症、虚血性心疾患および糖尿病から選ばれる疾患の予防及び/又は治療用である、[1]~[6]のいずれか一に記載のカルボン酸誘導体若しくはその医薬上許容される塩またはそれらの水和物若しくは溶媒和物。
上記化合物(I)における各基の具体例は次のとおりである。
(1)ハロゲン原子、
(2)C1-15アルキル(好ましくは、C1-6アルキル)、
(3)ハロ-C1-15アルキル、
(4)
(i) ハロゲン原子、
(ii) ヒドロキシ、
(iii) ニトロ、
(iv) シアノ、
(v) アミノ、
(vi) C1-15アルキル、
(vii) ハロ-C1-15アルキル、
(viii) C1-15アルコキシおよび
(ix) ハロ-C1-15アルコキシ
からなる群から選択される1~3個の置換基を有していてもよい、C6-14アリール、
(5)
(i) ハロゲン原子、
(ii) ヒドロキシ、
(iii) ニトロ、
(iv) シアノ、
(v) アミノ、
(vi) C1-15アルキル、
(vii) ハロ-C1-15アルキル、
(viii) C1-15アルコキシおよび
(ix) ハロ-C1-15アルコキシ
からなる群から選択される1~3個の置換基を有していてもよい、ヘテロアリール、
(6)C1-15アルコキシ、
(7)ハロ-C1-15アルコキシ、
などが挙げられる。
(8)シアノ基、
(9)ニトロ基、
(10)-NR11R12、
(11)-NR13COR14、
(12)-CONR15R16
(13)-OR17、
(14)-COR18および
(15)-C≡CR19
(式中、
R11、R12、R13、R14、R15およびR16は、同一または異なって、それぞれ、水素原子、C1-15アルキル基、C3-7シクロアルキル基、C6-14アリール基、C6-14アリール-C1-6アルキル基、ヘテロアリール基またはヘテロアリール-C1-6アルキル基を示すか、あるいはR11とR12、R13とR14は互いに結合して、炭素及びヘテロ原子を有していてもよいヘテロ環を形成し;
R17、R18およびR19は、それぞれ独立して水素原子、C1-15アルキル基、C3-7シクロアルキル基、C6-14アリール基、C6-14アリール-C1-6アルキル基、ヘテロアリール基またはヘテロアリール-C1-6アルキル基を示す。)
からなる群から選択される置換基が挙げられ、好ましくは、
(i) ハロゲン原子、
(ii) ヒドロキシ、
(iii) ニトロ、
(iv) シアノ、
(v) アミノ、
(vi) C1-15アルキル、
(vii) ハロ-C1-15アルキル、
(viii) C1-15アルコキシおよび
(ix) ハロ-C1-15アルコキシ
からなる群から選択される1~3個の置換基を有していてもよいC6-14アリールであり、より好ましくはハロ-C6-14アリールで置換されていてもよいC6-14アリールである。
R2の好適な例としては、C1-15アルキル基であり、より好ましくはC1-6アルキル基であり、最も好ましくはメチル基である。
R3の好適な例としては、水素原子またはC1-15アルキル基であり、より好ましくは水素原子またはC1-6アルキル基であり、最も好ましくは水素原子またはtert-ブチル基である。
R4の好適な例としては、水素原子、C1-15アルキル基またはC6-14アリール基であり、より好ましくは水素原子である。
mの好適な例としては、0~3の整数であり、より好ましくは0または1であり、最も好ましくは0である。
Xの好適な例としては、結合、酸素原子または硫黄原子であり、より好ましくは結合または酸素原子である。
Yの好適な例としては、カルボニル基または-CH(OR5)-で表される基である(ここでR5の好適な例としては、水素原子またはC1-15アルキルであり、より好ましくは水素原子またはC1-6アルキルであり、最も好ましくは水素原子またはメチルである)。
(1)ハロゲン原子、
(2)置換基を有していてもよいC1-15アルキル基、
(3)置換基を有していてもよいC3-7シクロアルキル基、
(4)置換基を有していてもよいC6-14アリール基、
(5)置換基を有していてもよいC6-14アリール-C1-8アルキル基、
(6)置換基を有していてもよいC6-14アリール-C2-6アルケニル基、
(7)置換基を有していてもよいC6-14アリールオキシ-C1-8アルキル基、
(8)置換基を有していてもよいヘテロアリール基または
(9)置換基を有していてもよいヘテロアリール-C1-3アルキル基
であり、より好ましくは、
(1)ハロゲン原子、
(2)C1-15アルキル基、
(3)置換基を有していてもよいC6-14アリール基または
(4)置換基を有していてもよいヘテロアリール基
であり、さらに好ましくは、
(1)ハロゲン原子、
(2)C1-6アルキル基、
(3)
(i) C1-6アルキル、
(ii) ハロ-C1-6アルキル、
(iii) C6-14アリールおよび
(iv) ハロ-C6-14アリール
からなる群から選択される1~3個の置換基を有していてもよいC6-14アリール基、または
(4)
(i) C1-6アルキル、
(ii) ハロ-C1-6アルキル、
(iii) C6-14アリールおよび
(iv) ハロ-C6-14アリール
からなる群から選択される1~3個の置換基を有していてもよいヘテロアリール基であり、
最も好ましくは、塩素原子、臭素原子、メチル基、フルオロビフェニル基、クロロビフェニル基またはフルオロフェニル-ピリジニル基である。
R6、R7およびR8は、同一または異なって、
(1)水素原子、
(2)ハロゲン原子、
(3)C1-6アルキル基、
(4)ハロ-C1-6アルキル基、
(5)
(i) ハロゲン原子、
(ii) ヒドロキシ、
(iii) ニトロ、
(iv) シアノ、
(v) アミノ、
(vi) C1-15アルキル、
(vii) ハロ-C1-15アルキル、
(viii) C1-15アルコキシおよび
(ix) ハロ-C1-15アルコキシ
からなる群から選択される1~3個の置換基を有していてもよい、C6-14アリール基、
(6)
(i) ハロゲン原子、
(ii) ヒドロキシ、
(iii) ニトロ、
(iv) シアノ、
(v) アミノ、
(vi) C1-15アルキル、
(vii) ハロ-C1-15アルキル、
(viii) C1-15アルコキシおよび
(ix) ハロ-C1-15アルコキシ
からなる群から選択される1~3個の置換基を有していてもよい、ヘテロアリール基、
(7)C1-6アルコキシ基、
(8)ハロ-C1-6アルコキシ基、
(9)シアノ基、
(10)ニトロ基、
(11)-NR11R12、
(12)-NR13COR14、
(13)-CONR15R16
(式中、
R11、R12、R13、R14、R15およびR16は、同一または異なって、それぞれ、水素原子、C1-6アルキル基、C3-7シクロアルキル基、C6-14アリール基、C6-14アリール-C1-6アルキル基、ヘテロアリール基またはヘテロアリール-C1-6アルキル基を示すか、または
R11とR12、R13とR14は互いに結合して、ヘテロ環を形成する。)、
(14)-OR17、
(15)-COR18または
(16)-C≡CR19
(式中、R17、R18およびR19は、それぞれ独立して、水素原子、C1-6アルキル基、C3-7シクロアルキル基、C6-14アリール基、C6-14アリール-C1-6アルキル基、ヘテロアリール基またはヘテロアリール-C1-6アルキル基を示す。)を示し;
R10は、水素原子、C1-6アルキル基、C3-7シクロアルキル基、ハロ-C1-6アルキル基、C6-14アリール基、ハロ-C6-14アリール基、C6-14アリール-C1-6アルキル基、ヘテロアリール基またはヘテロアリール-C1-6アルキル基を示し;
E1は、酸素原子、硫黄原子または-NR20-(式中、R20は水素原子、C1-6アルキル基、C3-7シクロアルキル基、C6-14アリール基、C6-14アリール-C1-6アルキル基またはヘテロアリール-C1-6アルキル基を示す。〕
から選択される基である。
R6、R7およびR8で示されるハロゲン原子としては、フッ素原子、臭素原子、塩素原子、ヨウ素原子が挙げられる。
R6、R7およびR8で示されるハロ-C1-6アルキル基としては、C1-6アルキル基をハロゲン原子で置換してなる基が挙げられ、例えばフルオロメチル、ジフルオロメチル、トリフルオロメチル、クロロメチル、2,2,2-トリフルオロエチル、ペンタフルオロエチル等が挙げられる。
R6、R7およびR8で示されるC6-14アリール基としては、R4で示される「置換基を有していてもよいアリール基」の「アリール基」と同様の基が挙げられるが、好ましくは、フェニル基である。
R6、R7およびR8で示されるヘテロアリール基としては、Zで示される「置換基を有していてもよいヘテロアリール基」の「ヘテロアリール基」と同様の基が挙げられるが、好ましくはピリジル、ピリミジルが挙げられる。
R6、R7およびR8で示されるアルコキシ基としては、例えばC1-15アルコキシ基が挙げられ、具体的には、例えば、メトキシ、エトキシが挙げられる。
R6、R7およびR8で示されるハロアルコキシ基としては、ハロゲン原子が置換した前記アルコキシ基が挙げられ、例えばトリフルオロメトキシ、2,2,2-トリフルオロエトキシ、ジフルオロメトキシ等が挙げられる。
R9およびR10で示されるC1-6アルキル基としては、R1およびR2で示されるC1-6アルキル基と同様の基が挙げられる。
R9およびR10で示されるC3-7シクロアルキル基としては、R1およびR2で示されるC3-7シクロアルキル基と同様の基が挙げられるが、好ましくは、シクロヘキシルである。
R9およびR10で示されるハロ-C1-6アルキル基としては、例えばフルオロメチル、ジフルオロメチル、トリフルオロメチル、クロロメチル、2,2,2-トリフルオロエチル、ペンタフルオロエチル等が挙げられる。
R9およびR10で示されるC6-14アリール基としては、R4で示されるアリール基と同様の基が挙げられるが、好ましくは、フェニル基である。
R9およびR10で示されるハロ-C6-14アリール基として好ましくは、クロロフェニル、ブロモフェニルが挙げられる。
R9およびR10で示されるヘテロアリール基としては、Zで示されるヘテロアリール基と同様の基が挙げられるが、好ましくは、ピリジル、ピリミジルである。
R10で示されるヘテロアリール-C1-6アルキル基としては、Zで示されるヘテロアリール-C1-3アルキル基と同様の基が挙げられる。
R11、R12、R13、R14、R15およびR16で示されるC3-7シクロアルキル基としては、R1およびR2で示されるC3-7シクロアルキル基と同様の基が挙げられるが、好ましくはシクロヘキシルである。
R11、R12、R13、R14、R15およびR16で示されるC6-14アリール基としては、R4で示されるアリール基と同様の基が挙げられるが、好ましくはフェニル基である。
R11、R12、R13、R14、R15およびR16で示されるC6-14アリール-C1-6アルキル基としては、Zで示されるC6-14アリール-C1-6アルキル基と同様の基が挙げられる。
R11、R12、R13、R14、R15およびR16で示されるヘテロアリール基としては、Zで示されるヘテロアリール基と同様の基が挙げられ、好ましくはピリジル、ピリミジルである。
R11、R12、R13、R14、R15およびR16で示されるヘテロアリール-C1-6アルキル基としては、Zで示されるヘテロアリールアルキル基と同様の基が挙げられる。
R11とR12、R13とR14で示されるヘテロ環としては、環構成原子として炭素原子以外に酸素原子、硫黄原子および窒素原子から選ばれるヘテロ原子を1~3個含有する炭素数2~10の非芳香族複素環基が挙げられ、例えばアゼチジニル、ピロリジニル、ピペリジノ、ピペラジノ、モルホリノ、1,2,5,6-テトラヒドロピリジル、チオモルホリノ、オキソチオモルホリノ、ジオキソチオモルホリノ、3-アザスピロ[5,5]ウンデシル、1,3,8-トリアザスピロ[4,5]デシル等が挙げられる。
R17、R18、R19およびR20で示されるC3-7シクロアルキル基としては、R1で示されるC3-7シクロアルキル基と同様の基が挙げられるが、好ましくはシクロヘキシルである。
R17、R18、R19およびR20で示されるC6-14アリール基としては、R4で示されるC6-14アリール基と同様の基が挙げられるが、好ましくはフェニル基である。
R17、R18、R19およびR20で示されるC6-14アリール-C1-8アルキル基としては、Zで示されるC6-14アリール-C1-8アルキル基と同様の基が挙げられる。
R17、R18およびR19で示されるヘテロアリール基としては、Zで示されるヘテロアリール基と同様の基が挙げられるが、好ましくはピリジル、ピリミジルである。
R17、R18、R19およびR20で示されるヘテロアリール-C1-6アルキル基としては、Zで示されるヘテロアリール-C1-3アルキル基と同様の基が挙げられる。
R1およびR2が、同一または異なって、C1-15アルキル基を示し、
R3が、水素原子またはC1-15アルキル基を示し;
R4が、水素原子を示し;
mが、0を示し;
Xが、結合または酸素原子を示し;
Yが、カルボニル基または-CH(OR5)-(式中、R5は、水素原子またはC1-15アルキル基を示す)で表される基を示し;
Zが、ハロゲン原子、C1-15アルキル基、置換基を有していてもよいC6-14アリール基または置換基を有していてもよいヘテロアリール基を示す、一般式(I)で示されるカルボン酸誘導体が挙げられる。
R1およびR2が、同一または異なって、C1-6アルキル基を示し、
R3が、水素原子またはC1-6アルキル基を示し;
R4が、水素原子を示し;
mが、0を示し;
Xが、結合または酸素原子を示し;
Yが、カルボニル基または-CH(OR5)-(式中、R5は、水素原子またはC1-6アルキル基を示す)で表される基を示し;
Zが、
(1) ハロゲン原子、
(2) C1-6アルキル基、
(3)
(i) C1-6アルキル、
(ii) ハロ-C1-6アルキル、
(iii) C6-14アリールおよび
(iv) ハロ-C6-14アリール
からなる群から選択される1~3個の置換基を有していてもよい、C6-14アリール基または
(4)
(i) C1-6アルキル、
(ii) ハロ-C1-6アルキル、
(iii) C6-14アリールおよび
(iv) ハロ-C6-14アリール
からなる群から選択される1~3個の置換基を有していてもよい、ヘテロアリール基を示す、一般式(I)で示されるカルボン酸誘導体が挙げられる。
本発明において、化合物(I)またはその医薬上許容される塩は、溶媒和物(例えば水和物)、生体内において代謝されて化合物(I)またはその医薬上許容される塩に変換されるプロドラッグ、または前記化合物(I)の活性代謝物も全て含むものである。
化合物(I)のうちY部分がカルボニル基である一般式(I-1)で表される化合物(以下、化合物(I-1)と記載)、(I-2)で表される化合物(以下、化合物(I-2)と記載)は、例えば以下の方法により製造することができる(製造方法1)。
アルキル鎖上に脱離基を有する一般式(II-1)で表される化合物(以下、化合物(II-1)などと記載。合成法は後述)を塩基の存在下、一般式(III-1)で表されるアルコール(チオール)誘導体(以下、化合物(III-1)などと記載)と反応させることで、エーテル(チオエーテル)化合物である化合物(I-1)を得ることができる(工程1)。さらに本化合物を脱エステル化してカルボン酸体である化合物(I-2)へと変換することができる(工程2)。なお、原料化合物である化合物(III-1)は、通常、公知の方法により容易に合成される。
ここで、R3aで示される「アルキル基」としては、R3で示される「置換基を有していてもよいアルキル基」の「アルキル基」と同様の基が挙げられる。
Z1で示される「置換されていてもよいアリール基」としては、Zで示される「置換基を有していてもよいアリール基」の「アリール基」と同様の基が挙げられる。
Z1で示される「置換されていてもよいヘテロアリール基」としては、Zで示される「置換基を有していてもよいヘテロアリール基」の「ヘテロアリール基」と同様の基が挙げられる。
また、一般式(I-1)の化合物は、例えば以下の方法によっても製造することができる(製造方法2)。
一般式(I-1)で表されるエーテル(チオエーテル)化合物はアルキル鎖上に脱離基を有する一般式(II-1)で表される化合物(合成法は後述)を塩基の存在下、一般式(III-2)で表される金属アルコキシド誘導体と反応させることによっても、得ることができる(工程3)。なお、原料化合物である化合物(III-2)は、通常、公知の方法により容易に合成される。
一般式(I)で表される化合物のうちY部分が-CH(OH)-である一般式(I-3)で表される化合物(以下、化合物(I-3)などと記載)、一般式(I-4)で表される化合物(以下、化合物(I-4)と記載)は、例えば以下の方法により製造することができる(製造方法3)。
製造方法1または2で得られる化合物(I-1)を還元することにより、アルコール体(化合物(I-3))が得られる(工程4)。さらに本化合物を脱エステル化してカルボン酸体(化合物(I-4))へと変換することができる(工程5)。
一般式(I)のZがアリール基、またはヘテロアリール基であり、そのアリール基またはヘテロアリール基の環上にハロゲン原子、トリフルオロメタンスルホニルオキシ基などの脱離基を有する、一般式(I-5)で表される化合物(以下、化合物(I-5)と記載)と一般式(III-3)で表されるホウ素化合物(以下、化合物(III-3)と記載)または一般式(III-4)で表されるスズ化合物(以下、化合物(III-4)と記載)とを、金属触媒の存在下にて反応させることで、アリール基またはヘテロアリール基を導入した化合物(I-6)を得ることができる(工程6)。さらに本化合物を脱エステル化してカルボン酸体である化合物(I-7)へと変換することができる(工程7)。また、製造方法3と同様にしてアルコール体である化合物(I-8)へと変換することができ(工程8)、さらに、脱エステル化してカルボン酸体である化合物(I-9)へと変換できる(工程9)。なお、原料化合物である化合物(III-3)、化合物(III-4)は、通常、公知の方法により容易に合成される。
Z2およびRaで示される「ヘテロアリール基」としては、Zで示される「置換基を有していてもよいヘテロアリール基」の「ヘテロアリール基」と同様の基が挙げられる。
RbおよびRcで示される「アルキル基」としては、R1およびR2で示される「置換基を有していてもよいアルキル基」の「アルキル基」と同様の基が挙げられる。
工程8は、製造方法3の工程4と同様の方法にて実施することができる。
製造方法3で得られる化合物(I-3)の水酸基をアルキル化することにより、化合物(I-10)を得ることができる(工程10)。さらに本化合物を脱エステル化することにより、化合物(I-11)を製造することができる(工程11)。
R5’で示される「アルキル基」としては、R1およびR2で示される「置換基を有していてもよいアルキル基」の「アルキル基」と同様の基が挙げられる。
製造方法3の工程4によって得られる化合物(I-3)のアルコール部分を、光学活性なカルボン酸またはその誘導体を用いてエステルである一般式(I-12)で表される化合物(以下、化合物(I-12)と記載)とし(工程12)、得られたジアステレオマー混合物を分割(工程13)後、エステルの切断を行い光学活性なアルコール体(一般式(I-14)で表される化合物;以下、化合物(I-14)と記載)を得ることができる(工程14)。さらに本化合物を脱エステル化してカルボン酸体(一般式(I-15)で表される化合物;以下、化合物(I-15)と記載)へと変換することができる(工程15)。なお、工程14と工程15は順序を逆にしても良いし、同時に行っても良い。
製造方法1の工程1で得られる化合物(I-1)に対して不斉還元を行う(工程16)ことによっても、光学活性なアルコール体である化合物(I-14)を得ることができる。さらに、化合物(I-14)を脱エステル化してカルボン酸体である化合物(I-15)へと変換することができる(工程17)。
なお、製造方法6または7によって得られた化合物(I-15)は、有機合成における公知の方法、例えば、キラルカラムクロマトグラフィーによる精製、あるいは(S)または(R)-フェニルエチルアミン等の光学活性な有機アミンによる塩化と結晶化を行うことにより、光学純度を上げることができる。
上記製造方法で使用した化合物(II-1)は、例えば以下に示すチオール基を有する一般式(V)で表される化合物(以下、化合物(V)と記載)を出発原料として、例えば、以下の製造方法8または9に示す方法によって製造することができる。なお、化合物(V)は、国際公開第2006/049232号パンフレットに記載の方法に従って製造することができる。
カルボン酸である化合物(V)をハロメチル化することによって、ハロケトン(II-1)を得ることができる。(工程18)
ハロ酢酸またはその塩から調製される金属エノラートを作用させる反応は、文献公知の方法で化合物(V)から容易に合成可能なメチルあるいはエチルエステル等の低級アルキルエステルに対して、ハロ酢酸またはその塩、n-ブチルマグネシウムクロリド等のグリニャール試薬、およびジイソプロピルアミンを加えることによって行うことができる。これらの使用量は、当業者であれば適宜決定することが可能である。反応は、通常、反応に影響を及ぼさない溶媒中で、-50℃から100℃、好ましくは-10℃から50℃の範囲で実施することができる。反応に影響を及ぼさない溶媒としては、テトラヒドロフラン、ジエチルエーテル等のエーテル類が挙げられる。
化合物(V)から一般式(VI)で表される化合物(以下、化合物(VI)と記載する)を製造し(工程19)、これを用いてハロゲン化を行うことにより、ハロケトン(II-1)を製造することができる(工程20)。
また、Zがシクロアルキル基、アリールアルキル基、アリールオキシアルキル基、ヘテロアリール基を示す場合についても上記方法に従うことにより、同様に製造することができる。
また、このようにして得られる化合物(I)は必要により塩酸、臭化水素酸等の無機酸、トリフルオロ酢酸、酢酸、メタンスルホン酸、ベンゼンスルホン酸等の有機酸、ナトリウム、カリウム、カルシウム等のアルカリ金属、ジシクロヘキシルアミン等の有機塩基、リジン、アルギニン等のアミノ酸と処理することによりそれらの塩とすることができる。
さらに、本発明の化合物(I)は、糖尿病に合併した高脂血症の予防及び/又は治療薬としても有用である。糖尿病に合併した高脂血症とは、糖尿病患者が高脂血症を併発した場合をいい、糖尿病性高脂血症と称することもある。
本明細書中、「糖尿病患者が高脂血症を併発した病態」とは、糖尿病の治療により血糖値に改善効果が見られても、TG値、LDL-C値、HDL-C値などが正常値を示さない病態をいい、これらの病態に対して本発明の医薬を治療目的で適用することができる。また、糖尿病患者又はその再発のおそれのある患者で、TG値、LDL-C値、HDL-C値などが正常値の範囲内であっても、本発明の医薬を治療若しくは予防目的で適用することが可能である。
高脂血症をリポタンパク表現型により分類するWHO分類が知られている。トリグリセリドが高値を示す表現型としては、I型高脂血症、IIb型高脂血症、III型高脂血症、IV型高脂血症、V型高脂血症などがあり、その中でも特に血清TGが高値かつ/またはHDLが低値を示す糖尿病が強く疑われる人もしくは糖尿病の可能性を否定できない人が本発明の医薬の好ましい適用対象である。もっとも、その他の分類に属する患者で、糖尿病に合併した高脂血症と診断された患者に対しても本発明の医薬を適用することもできる。また、糖尿病患者又はその再発のおそれのある患者で、TG値、LDL-C値、HDL-C値などが正常値の範囲内を示す患者であっても、本発明の医薬を治療若しくは予防目的で適用することが可能である。
ここで、糖尿病とは空腹時血糖値が126mg/dL以上、または、75g糖負荷試験2時間値が200mg/dL以上である場合を指す。また、随時血糖値が200mg/dL以上の場合も糖尿病とする。
本発明の好ましい化合物、なかでも、実施例12の化合物は、CYPによる代謝に関与しないため、CYPによる代謝に関与する薬剤(例えば、フルバスタチン等)との併用が可能であり、安全性の高い優れた高脂血症等の予防または治療薬となりうる。
2-{[4-(クロロアセチル)-1,3-チアゾール-2-イル]チオ}-2-メチルプロピオン酸 tert-ブチルエステル
1H-NMR(CDCl3,300MHz)
δ:1.45(9H,s),1.66(6H,s),4.88(2H,s),8.26(1H,s).
LC-MS:280(M-tBu+H)+
2-[(4-{2-[(4’-フルオロビフェニル-4-イル)オキシ]-1-ヒドロキシエチル}-1,3-チアゾール-2-イル)チオ]-2-メチルプロピオン酸
2-[(4-{[(4’-フルオロビフェニル-4-イル)オキシ]アセチル}-1,3-チアゾール-2-イル)チオ]-2-メチルプロピオン酸 tert-ブチルエステル
1H-NMR(CDCl3,300MHz)
δ:1.43(9H,s),1.68(6H,s),5.45(2H,s),6.91~7.13(4H,m),7.45~7.51(4H,m),8.29(1H,s).
LC-MS:432(M-tBu+H)+
2-[(4-{2-[(4’-フルオロビフェニル-4-イル)オキシ]-1-ヒドロキシエチル}-1,3-チアゾール-2-イル)チオ]-2-メチルプロピオン酸 tert-ブチルエステル
1H-NMR(CDCl3,300MHz)
δ:1.43(9H,s),1.59(6H,s),2.99(1H,d,J=4.5Hz),4.19(1H,dd,J=7.5Hz,9.6Hz),4.42(1H,d,J=3.9Hz,9.6Hz),5.25(1H,m),6.99(2H,d,J=6.6Hz),7.10(2H,t,J=6.9Hz),7.42~7.51(5H,m).
LC-MS:490(M+H)+
2-[(4-{2-[(4’-フルオロビフェニル-4-イル)オキシ]-1-ヒドロキシエチル}-1,3-チアゾール-2-イル)チオ]-2-メチルプロピオン酸
1H-NMR(CDCl3,300MHz)
δ:1.61(3H,s),1.64(3H,s),4.23(1H,dd,J=6.8Hz,9.6Hz),4.39(1H,dd,J=3.72Hz,9.6Hz),5.26(1H,m),6.97(2H,d,J=8.8Hz),7.10(2H,t,J=8.8Hz),7.43~7.50(5H,m).
LC-MS:434(M+H)+
2-[(4-{[(4’-フルオロビフェニル-4-イル)オキシ]アセチル}-1,3-チアゾール-2-イル)チオ]-2-メチルプロピオン酸
1H-NMR(CDCl3,300MHz)
δ:1.69(6H,s),5.35(2H,s),7.01(2H,d,J=8.7Hz),7.09(2H,t,J=8.7Hz),7.44~7.50(4H,m),8.25(1H,s).
LC-MS:432(M+H)+
2-[(4-{[(4’-クロロビフェニル-4-イル)オキシ]アセチル}-1,3-チアゾール-2-イル)チオ]-2-メチルプロピオン酸
1H-NMR(CDCl3,300MHz)
δ:1.70(6H,s),5.36(2H,s),7.04(2H,d,J=8.7Hz),7.37(2H,d,J=8.7Hz),7.44~7.50(4H,m),8.26(1H,s).
LC-MS:446(M+H)+
2-[(4-{2-[(4’-クロロビフェニル-4-イル)オキシ]-1-ヒドロキシエチル}-1,3-チアゾール-2-イル)チオ]-2-メチルプロピオン酸
1H-NMR(CDCl3,300MHz)
δ:1.61(3H,s),1.64(3H,s),4.24(1H,dd,J=6.8Hz,9.5Hz),4.39(1H,dd,J=3.72Hz,9.6Hz),5.27(1H,m),6.99(2H,d,J=8.7Hz),7.36~7.49(6H,m).
LC-MS:450(M+H)+
2-[(4-{2-[(4’-フルオロビフェニル-4-イル)オキシ]-1-メトキシエチル}-1,3-チアゾール-2-イル)チオ]-2-メチルプロピオン酸
1H-NMR(CDCl3,300MHz)
δ:1.61(3H,s),1.64(3H,s),3.51(3H,s),4.32(1H,d,J=5.1Hz),4.81(1H,t,J=8.6Hz),6.96(2H,d,J=8.7Hz),7.08(2H,t,J=8.6Hz),7.38~7.50(5H,m).
LC-MS:448(M+H)+
2-{[4-(2-{[5-(4-フルオロフェニル)ピリジン-2-イル]オキシ}-1-ヒドロキシエチル)-1,3-チアゾール-2-イル]チオ}-2-メチルプロピオン酸
2-[(4-{[(5-ブロモピリジン-2-イル)オキシ]-アセチル}-1,3-チアゾール-2-イル)チオ]-2-メチルプロピオン酸 tert-ブチルエステル
1H-NMR(CDCl3,300MHz)
δ:1.43(9H,s),1.68(6H,s),5.67(2H,s)6.85(1H,d,J=8.6Hz),7.69(1H,dd,J=2.4Hz,8.6Hz),8.05(1H,d,J=2.4Hz),8.21(1H,s).
2-{[4-(2-{[5-(4-フルオロフェニル)ピリジン-2-イル]オキシ}-1-ヒドロキシエチル)-1,3-チアゾール-2-イル]チオ}-2-メチルプロピオン酸
1H-NMR(CDCl3,300MHz)
δ:1.66(6H,s),4.68(1H,dd,J=6Hz,12.3Hz),4.78(1H,dd,J=2.4Hz,12Hz),5.26(1H,m),6.86(1H,d,J=8.4Hz),7.15(2H,t,J=8.7Hz),7.38(1H,s),7.44~7.49(2H,m),7.79(1H,dd,J=2.7Hz,9Hz),8.29(1H,d,J=2.7Hz).
LC-MS:435(M+H)+
2-{[4-アセチル-1,3-チアゾール-2-イル]チオ}-2-メチルプロピオン酸 tert-ブチルエステル
1H-NMR(CDCl3,300MHz)
δ:1.43(9H,s),1.71(6H,s),2.66(3H,s),8.13(1H,s).
LC-MS:301(M+H)+
2-{[4-ブロモアセチル-1,3-チアゾール-2-イル]チオ}-2-メチルプロピオン酸 tert-ブチルエステル
1H-NMR(CDCl3,300MHz)
δ:1.43(9H,s),1.63(6H,s),4.69(2H,s),8.26(1H,s).
LC-MS:324(M-tBu+H)+
2-[(4-{(1S)-2-[(4’-フルオロビフェニル-4-イル)オキシ]-1-ヒドロキシエチル}-1,3-チアゾール-2-イル)チオ]-2-メチルプロピオン酸
2-[(4-{[(4’-フルオロビフェニル-4-イル)オキシ]アセチル}-1,3-チアゾール-2-イル)チオ]-2-メチルプロピオン酸 tert-ブチルエステル
実施例9で得られたブロムケトン体10.462gをアセトン300mLに溶解し、4’-フルオロビフェニル-4-オール5.17g、炭酸カリウム3.80gを加え6時間20分加熱還流した。固体をろ去後、ろ液の溶媒を留去し、残渣をトルエン100mLに溶解し、水酸化ナトリウム水溶液(1mol/L)50mLで3回洗浄後、飽和食塩水50mLで洗浄し、無水硫酸ナトリウムで乾燥した。溶媒を留去後カラムクロマトグラフィーで精製(3回に分割。モリテックス社purif pakTM Si60μm、サイズ200使用。展開溶媒:ヘキサン/酢酸エチル=90/10~60/40)して表題化合物を7.36g得た。
1H-NMR(CDCl3,300MHz)
δ:1.43(9H,s),1.68(6H,s),5.4(2H,s),7.00~7.13(4H,m),7.45~7.55(4H,m),8.29(1H,s).
2-[(4-{(1S)-2-[(4’-フルオロビフェニル-4-イル)オキシ]-1-ヒドロキシエチル}-1,3-チアゾール-2-イル)チオ]-2-メチルプロピオン酸 tert-ブチルエステル
(S)-(-)-2-メチル-CBS-オキサボロジン410mgとボラン-ジメチルスルフィド錯体(1mol/L塩化メチレン溶液)11.84mLを塩化メチレン30mLに溶解し、実施例2-1で得られたケトン体7.21gの塩化メチレン20mL溶液を室温で35分かけて滴下し、さらに3時間25分撹拌した。1mol/L塩酸水50mLを少しずつ加えて1時間撹拌後分液し、1mol/L塩酸水、飽和食塩水各50mLで順次洗浄した。無水硫酸ナトリウムで乾燥後、溶媒を留去し、再びテトラヒドロフラン50mLに溶解し、10%炭酸カリウム水溶液50mLを加えて1時間撹拌した。酢酸エチルで抽出(100mL、50mL)し、飽和食塩水で洗浄後、無水硫酸ナトリウムで乾燥した。溶媒を留去後、カラムクロマトグラフィーで精製(2回に分割。モリテックス社purif pakTM Si60μm、サイズ200使用。展開溶媒:ヘキサン/酢酸エチル=90/10~50/50)して、表題化合物を5.80g得た。
1H-NMR(CDCl3,300MHz)
δ:1.43(9H,s),1.64(6H,s),2.99(1H,d,J=4.5Hz),4.19(1H,dd,J=7.5Hz,9.6Hz),4.42(1H,d,J=3.9Hz,9.6Hz),5.25(1H,m),6.99(2H,d,J=6.6Hz),7.10(2H,t,J=6.9Hz),7.42~7.51(5H,m).
2-[(4-{(1S)-2-[(4’-フルオロビフェニル-4-イル)オキシ]-1-ヒドロキシエチル}-1,3-チアゾール-2-イル)チオ]-2-メチルプロピオン酸
実施例10-2で得られた2-[(4-{(1S)-2-[(4’-フルオロビフェニル-4-イル)オキシ]-1-ヒドロキシエチル}-1,3-チアゾール-2-イル)チオ]-2-メチルプロピオン酸 tert-ブチルエステル904mgをジオキサン5mLに溶解し、濃塩酸0.5mLを加えて油浴温度95℃で3時間30分撹拌した。反応液を放冷後、水酸化カリウム水溶液(1mol/L)15mLを加え撹拌した。これをヘキサンとテトラヒドロフランの混合溶媒(2/1)で洗浄し、水層を1mol/L塩酸水でpHを1程度に調整し、酢酸エチル100mLで抽出し、飽和食塩水で洗浄した。無水硫酸ナトリウムで乾燥後、溶媒を留去し、残渣をカラムクロマトグラフィーで精製(山善HI-FLASHTM COLUMN size3L、溶出溶媒:ヘキサン/酢酸エチル=70/30~0/100)し、目的のカルボン酸の粗生成物を624mg得た。同様の反応をアルコール体4.89gを用いて繰り返し実施し、目的のカルボン酸の粗生成物を3.68g得た。得られたカルボン酸4.33gをヘキサン60mLと酢酸エチル50mLの混合溶媒に溶解し、(R)-フェネチルアミン1.27mLを加え一夜放置した。析出した固体(異性体混合比 73.46:26.54。異性対比は、ダイセル社製Chiralpak AD-H(4.6×250mm、溶出溶媒:ヘキサン/イソプロピルアルコール/トリフロロ酢酸=70/30/0.1)を用いた分析により決定した。)をろ去し、ろ液(異性体混合比 99.4:0.6)の溶媒を留去したのち再びヘキサン30mLと酢酸エチル20mLの混合溶媒に湯浴で加温して溶解し、さらにヘキサンを10mL加えて室温で一夜放置して析出した固体をろ取して塩を3.137g得た(異性体比 99.79:0.21)。
上記分割工程で得られた塩を水30mLとエタノール10mLの混合溶媒に溶解し、1mol/L塩酸水でpHを1程度に調整した。溶媒を留去後、酢酸エチル100mLで抽出し、飽和食塩水にて洗浄後無水硫酸ナトリウムで乾燥した。溶媒を留去後、残渣をカラムクロマトグラフィーで精製(山善HI-FLASHTM COLUMN sizeL、溶出溶媒:ヘキサン/酢酸エチル=70/30~0/100)して、カルボン酸を2.19g(塩化の前からの回収率50.5%)得た。ここから486mg分とりわけて、ヘキサン10mLと酢酸エチル4mLに加温して溶解し、放冷すると結晶が析出したので、ろ取して目的のカルボン酸を白色結晶として357mg得た(回収率73.5%)。同様に残りのカルボン酸を用いて、白色結晶を1.235g得た(回収率74.1%)。2回に分けて得られた結晶を合わせてヘキサン35mLと酢酸エチル20mLで再結晶を行い、表題化合物を1.305g得た。なお、絶対構造は、実施例12の方法にて得られる化合物と比旋光度の符合が一致することからS体と決定した。
1H-NMR(DMSO-d6,300MHz)
δ:1.62(3H,s),1.64(3H,s),4.24(1H,dd,J=6.9Hz,9.6Hz),4.39(1H,dd,J=3.6Hz,9.6Hz),5.27(1H,m),6.98(2H,d,J=9.0Hz),7.10(2H,t,J=9.0Hz),7.44~7.51(5H,m).
LC-MS:434(M+H)+
旋光度:[α]D 20=+51.0°(0.058g、エタノール、10mL、100mm)
光学純度:99.8%ee以上[Chiralpak AD-H(4.6×250mm)、溶出溶媒:ヘキサン/イソプロピルアルコール/トリフロロ酢酸=70/30/0.1、検出波長260nm]
2-[(4-{(1R)-2-[(4’-フルオロビフェニル-4-イル)オキシ]-1-ヒドロキシエチル}-1,3-チアゾール-2-イル)チオ]-2-メチルプロピオン酸
(S)-(-)-2-メチル-CBS-オキサボロジンの代わりに、(R)-(+)-2-メチル-CBS-オキサボロジンを用いて、実施例10と同様の反応を行うことにより表題化合物を791mg得た。
1H-NMR(DMSO-d6,300MHz)
δ:1.62(3H,s),1.64(3H,s),4.24(1H,dd,J=6.6Hz,9.6Hz),4.39(1H,dd,J=3.6Hz,9.6Hz),5.27(1H,m),6.98(2H,d,J=8.7Hz),7.10(2H,t,J=8.4Hz),7.44~7.51(5H,m).
LC-MS:434(M+H)+
旋光度:[α]D 20=-51.0°(0.044g、エタノール、10mL、100mm)
光学純度:99.8%[Chiralpak AD-H(4.6×250mm)、溶出溶媒:ヘキサン/イソプロピルアルコール/トリフロロ酢酸=70/30/0.1、検出波長260nm]
2-[(4-{(1S)-2-[(4’-フルオロビフェニル-4-イル)オキシ]-1-ヒドロキシエチル}-1,3-チアゾール-2-イル)チオ]-2-メチルプロピオン酸
1-{2-[(2-tert-ブトキシ-1,1-ジメチル-2-オキソエチル)チオ]-1,3-チアオゾール-4-イル}-2-[(4’-フルオロビフェニル-4-イル)オキシ]エチル (2R)-3,3,3-トリフルオロ-2-メトキシ-2-フェニルプロピオン酸
結晶A
δ:1.42(9H,s),1.59(3H,s),1.60(3H,s),3.50(3H,s),4.42~4.55(2H,m),6.59(1H,m),6.90(2H,d,J=8.7Hz),7.07(2H,t,J=8.7Hz),7.34~7.55(10H,m).
LC-MS:706(M++1)
結晶B
δ:1.41(9H,s),1.58(3H,s),1.62(3H,s),3.62(3H,s),4.41~4.59(2H,m),6.62(1H,m),6.97(2H,d,J=8.7Hz),7.07~7.13(3H,m),7.45~7.58(9H,m).
2-[(4-{(1S)-2-[(4’-フルオロビフェニル-4-イル)オキシ]-1-ヒドロキシエチル}-1,3-チアゾール-2-イル)チオ]-2-メチルプロピオン酸
実施例12-1で得られた結晶A900mgをテトラヒドロフラン10mLに溶解し、1mol/L水酸化ナトリウム水溶液1.9mLを加えて2時間10分加熱還流した。TLCにより、原料のアシル体が残っていることがわかったので、水酸化ナトリウム水溶液を0.6mL追加し、さらに7時間30分加熱還流した。放冷後、水10mLを加え、ジエチルエーテル20mLで抽出し、飽和重曹水、飽和食塩水で順次洗浄後、無水硫酸ナトリウムで乾燥した。溶媒を留去して得られた残渣をカラムクロマトグラフィーで精製(カラム:モリテックスpurif-pak SI 60,60g;溶出溶媒:ヘキサン/酢酸エチル=4/1→6/4)してアルコール体を623mg得た。これを581mg塩化メチレン1mLに溶解し、トリフルオロ酢酸1mLを加えて一夜撹拌した。溶媒を留去後、カラムクロマトグラフィーで精製(カラム:モリテックスpurif-pak SI 30,60g;溶出溶媒:ヘキサン/酢酸エチル=6/4→酢酸エチルのみ)して、表題化合物を311mg得た。
H-NMR(CDCl3,300MHz)
δ:1.62(3H,s),1.64(3H,s),4.23(1H,dd,J=6.8Hz,9.6Hz),4.40(1H,dd,J=3.72Hz,9.6Hz),5.27(1H,m),6.98(2H,d,J=8.8Hz),7.10(2H,t,J=8.8Hz),7.43~7.50(5H,m).
LC-MS:434(M+H)+
旋光度:[α]21.8 D +47.75(c 1.00,EtOH)
2-[(4-{(1R)-2-[(4’-フルオロビフェニル-4-イル)オキシ]-1-ヒドロキシエチル}-1,3-チアゾール-2-イル)チオ]-2-メチルプロピオン酸
実施例12-1で得られた結晶B800mg用いて、実施例12-2と同様にして、表題化合物を310mg得た。
NMR(CDCl3,300MHz)
δ:1.61(3H,s),1.64(3H,s),4.24(1H,dd,J=6.8Hz,9.6Hz),4.40(1H,dd,J=3.72Hz,9.6Hz),5.27(1H,m),6.98(2H,d,J=8.8Hz),7.11(2H,t,J=8.8Hz),7.43~7.50(5H,m).
LC-MS:434(M+H)
旋光度 [α]22.3 D -51.07(c 1.00,EtOH)
ヒトペルオキシゾーム増殖薬活性化受容体(PPAR)αに対する転写活性化試験
10%牛胎児血清(FBS)を含むダルベッコ変法イーグル培地(DMEM)にて培養したCV-1細胞(CCL-70、大日本製薬社製)に、酵母の転写因子(GAL4)のDNA結合領域とヒトPPARαのリガンド結合領域との融合蛋白質(GAL4-hPPARαLBD,Diabetes 47:1841-1847, 1998により作製)および内部標準用のウミシイタケルシフェラーゼを発現するpBINDベクター(Promega社製)ならびにレポーターとなるホタルルシフェラーゼを発現するGAL4応答性TKベクター(Promega社製)をリポフェクトアミン2000(Invitrogen社製)を用いてトランスフェクションした。24時間後、被検化合物を添加した無血清培地に交換し、24時間後のルシフェラーゼ活性を測定した。
結果を表1に示す。
以上より、本発明化合物はヒトPPARα阻害作用を有することが明らかになった。
また、上表の通り、当該実験例において、化合物Aの転写活性化作用は10.41nmol/lであり、本発明の好ましい化合物、なかでも実施例12の化合物は、3倍以上強い活性を示した。
in vivoにおける脂質低下作用
1)正常ラットにおける血中トリグリセリド(TG)低下作用
SD系雄性ラット(セアック吉富社製)の7~9週齢を用いて試験を行った。試験化合物および対照化合物(GW-9578:J. Med. Chem. 1999, 42, 3785-3788)を1%エタノール、0.05% tween80(終濃度)により溶解または懸濁した後、0.5% hydroxypropylmethyl cellurose(HPMC)を加え所定の濃度に調製した液を1日1回4日間経口投与した。4日間投与後に非絶食下頸静脈より採血し、血中TGを酵素法にて測定した。低下率はvehicle投与群の平均血中TG量から薬物投与群の平均血中TG量を引いた値のvehicle投与群の平均血中TG量に対する割合を求めることで算出した。
結果を表2に示す。
また、実施例12の化合物は、0.01mg/kg投与により、15.1%のTG低下作用を示したのに対し、化合物Aは同用量ではTG低下作用をほとんど示さなかった(TG低下作用:0.7%)。したがって、実験例12の化合物は、化合物Aと比較して、低用量から優れたTG低下作用を示すことが判明した。
SD系雄性ラット(セアック吉富社製)の8週齢に標準飼料CE-2(日本クレア社製)に1%コレステロール、2%オリーブ油および0.2%コール酸を添加した飼料を試験化合物投与1週間前より投与終了日まで処置した。試験化合物および対照化合物(GW-9578)を1%エタノール、0.05% Tween80(終濃度)により溶解または懸濁した後、0.5% hydroxypropylmethyl cellurose(HPMC)を加え所定の濃度に調製した液を1日1回5日間経口投与した。5日間投与後に非絶食下頸静脈より採血し、血中脂質を酵素法にて測定した。低下率はvehicle投与群の平均血中トリグリセリド(TG)量(または平均血中総コレステロール(TC)量)から薬物投与群の平均血中TG量(または平均血中TC量)を引いた値のvehicle投与群の平均血中TG量(または平均血中TC量)に対する割合を求めることで算出した。
結果を表3に示す。
以上の結果より本発明化合物は優れた血中脂質低下作用を有することが明らかになった。
代謝分子種同定試験(ミクロソームによる酸化的代謝)
CYP分子種同定用反応液として、ミクロソームを含有する反応液[14Cで標識された被験化合物(2μmol/L)、ミクロソーム(0.5mg protein/mLのヒト肝ミクロソームあるいは50pmol CYP/mLのCYP発現系ミクロソーム(Controlミクロソーム,CYP1A2,CYP2A6,CYP2B6,CYP2C8,CYP2C9,CYP2C19,CYP2D6,CYP2E1またはCYP3A4))、EDTA(0.05mmol/L)およびNa-Kリン酸緩衝液(pH7.4, 0.1mol/L)]を調製し、37℃で5分間プレインキュベーションした後、NADPH生成系の溶液[β-NADP+(0.5mmol/L)、グルコース-6-フォスフェイト(G-6-P)(5.0mmol/L)、塩化マグネシウム(5.0mmol/L)およびG-6-P DH(1.0unit/mL)]をそれぞれ添加して反応を開始した。なお、CYP2A6およびCYP2C9のCYP発現系ミクロソームでは、Na-Kリン酸緩衝液(pH7.4, 0.1mol/L)に代えて、Tris-HCl緩衝液(pH7.4, 0.1mol/L)を使用した。
化合物Aについてはヒト肝ミクロソームにおいて酸化的代謝が認められたため、阻害剤を用いた検討を実施した。阻害剤を用いた検討からも、化合物Aの代謝に関与する主な酵素はCYP2C9であることを確認した。
本出願は、日本で出願された特願2008-306803(出願日:2008年12月1日)を基礎としており、それらの内容は本明細書に全て包含されるものである。
Claims (11)
- 下記式(I)
R1およびR2は、同一または異なって、水素原子もしくは置換基を有していてもよいアルキル基を示すか、またはR1およびR2は相互に結合して、置換基を有していてもよいシクロアルキル基を形成し;
R3は、水素原子または置換基を有していてもよいアルキル基を示し;
R4は、水素原子、置換基を有していてもよいアルキル基または置換基を有していてもよいアリール基を示し;
mは、0~3の整数を示し;
Xは、結合、酸素原子または硫黄原子を示し;
Yは、カルボニル基または-CH(OR5)-(式中、R5は、水素原子または置換基を有していてもよいアルキル基を示す)で表される基を示し;
Zは、
ハロゲン原子、
置換基を有していてもよいアルキル基、
置換基を有していてもよいシクロアルキル基、
置換基を有していてもよいアリール基、
置換基を有していてもよいアリールアルキル基、
置換基を有していてもよいアリールアルケニル基、
置換基を有していてもよいアリールオキシアルキル基、
置換基を有していてもよいヘテロアリール基または
置換基を有していてもよいヘテロアリールアルキル基を示す。〕で表されるチアゾール環を含むカルボン酸誘導体若しくはその医薬上許容される塩またはそれらの水和物若しくは溶媒和物。 - R1およびR2が、同一または異なって、C1-15アルキル基を示し、
R3が、水素原子またはC1-15アルキル基を示し;
R4が、水素原子を示し;
mが、0を示し;
Xが、結合または酸素原子を示し;
Yが、カルボニル基または-CH(OR5)-(式中、R5は、水素原子またはC1-15アルキル基を示す)で表される基を示し;
Zが、ハロゲン原子、C1-15アルキル基、置換基を有していてもよいC6-14アリール基または置換基を有していてもよいヘテロアリール基を示す、
請求項1または2に記載のカルボン酸誘導体若しくはその医薬上許容される塩またはそれらの水和物若しくは溶媒和物。 - R1およびR2が、同一または異なって、C1-6アルキル基を示し、
R3が、水素原子またはC1-6アルキル基を示し;
R4が、水素原子を示し;
mが、0を示し;
Xが、結合または酸素原子を示し;
Yが、カルボニル基または-CH(OR5)-(式中、R5は、水素原子またはC1-6アルキル基を示す)で表される基を示し;
Zが、
(1) ハロゲン原子、
(2) C1-6アルキル基、
(3)
(i) C1-6アルキル、
(ii) ハロ-C1-6アルキル、
(iii) C6-14アリールおよび
(iv) ハロ-C6-14アリール
からなる群から選択される1~3個の置換基を有していてもよい、C6-14アリール基または
(4)
(i) C1-6アルキル、
(ii) ハロ-C1-6アルキル、
(iii) C6-14アリールおよび
(iv) ハロ-C6-14アリール
からなる群から選択される1~3個の置換基を有していてもよい、ヘテロアリール基を示す、
請求項1または2に記載のカルボン酸誘導体若しくはその医薬上許容される塩またはそれらの水和物若しくは溶媒和物。 - 式(I)または式(I’)中、
Zにおける置換基を有していてもよいアリール基または置換基を有していてもよいヘテロアリール基が、下記式(Za~Zn)
R6、R7、R8、R9およびR10は、同一または異なって、水素原子、C1-6アルキル基、ハロ-C1-6アルキル基、C6-14アリール基またはハロ-C6-14アリール基を示し、
E1は、酸素原子、硫黄原子または-NR20-(式中、R20は水素原子、C1-6アルキル基、C3-7シクロアルキル基、C6-14アリール基、C6-14アリール-C1-6アルキル基またはヘテロアリール-C1-6アルキル基を示す)。〕
からなる群から選択される置換基で表される、請求項1~3のいずれか一項に記載のカルボン酸誘導体若しくはその医薬上許容される塩またはそれらの水和物若しくは溶媒和物。 - 2-[(4-{[(4’-フルオロビフェニル-4-イル)オキシ]アセチル}-1,3-チアゾール-2-イル)チオ]-2-メチルプロピオン酸;
2-[(4-{2-[(4’-フルオロビフェニル-4-イル)オキシ]-1-ヒドロキシエチル}-1,3-チアゾール-2-イル)チオ]-2-メチルプロピオン酸;
2-[(4-{[(4’-クロロビフェニル-4-イル)オキシ]アセチル}-1,3-チアゾール-2-イル)チオ]-2-メチルプロピオン酸;
2-[(4-{2-[(4’-クロロビフェニル-4-イル)オキシ]-1-ヒドロキシエチル}-1,3-チアゾール-2-イル)チオ]-2-メチルプロピオン酸;
2-[(4-{2-[(4’-フルオロビフェニル-4-イル)オキシ]-1-メトキシエチル}-1,3-チアゾール-2-イル)チオ]-2-メチルプロピオン酸;
2-{[4-(2-{[5-(4-フルオロフェニル)ピリジン-2-イル]オキシ}-1-ヒドロキシエチル)-1,3-チアゾール2-イル]チオ}-2-メチルプロピオン酸;
2-[(4-{(1S)-2-[(4’―フルオロビフェニル-4-イル)オキシ]-1-ヒドロキシエチル}-1,3-チアゾール-2-イル)チオ]-2-メチルプロピオン酸;
または
2-[(4-{(1R)-2-[(4’―フルオロビフェニル-4-イル)オキシ]-1-ヒドロキシエチル}-1,3-チアゾール-2-イル)チオ]-2-メチルプロピオン酸;
であるカルボン酸またはその誘導体若しくはその医薬上許容される塩またはそれらの水和物若しくは溶媒和物。 - 請求項1~6のいずれか一項に記載のカルボン酸誘導体若しくはその医薬上許容される塩またはそれらの水和物若しくは溶媒和物を有効成分として含有する、高脂血症、糖尿病に合併した高脂血症、動脈硬化症、虚血性心疾患および糖尿病から選ばれる疾患の予防及び/又は治療薬。
- 請求項1~6のいずれか一項に記載のカルボン酸誘導体若しくはその医薬上許容される塩またはそれらの水和物若しくは溶媒和物の、高脂血症、糖尿病に合併した高脂血症、動脈硬化症、虚血性心疾患および糖尿病から選ばれる疾患の予防及び/又は治療用医薬の製造のための使用。
- 請求項1~6のいずれか一項に記載のカルボン酸誘導体若しくはその医薬上許容される塩またはそれらの水和物若しくは溶媒和物、および医薬上許容される担体からなる医薬組成物。
- 請求項1~6のいずれか一項に記載のカルボン酸誘導体若しくはその医薬上許容される塩またはそれらの水和物若しくは溶媒和物を、それを必要とする対象に投与することを特徴とする、高脂血症、糖尿病に合併した高脂血症、動脈硬化症、虚血性心疾患および糖尿病から選ばれる疾患の予防及び/又は治療方法。
- 高脂血症、糖尿病に合併した高脂血症、動脈硬化症、虚血性心疾患および糖尿病から選ばれる疾患の予防及び/又は治療用である、請求項1~6のいずれか一項に記載のカルボン酸誘導体若しくはその医薬上許容される塩またはそれらの水和物若しくは溶媒和物。
Priority Applications (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020117015086A KR101290868B1 (ko) | 2008-12-01 | 2009-12-01 | 티아졸환을 포함하는 카르복실산 유도체 및 그의 의약 용도 |
AU2009323367A AU2009323367B2 (en) | 2008-12-01 | 2009-12-01 | Carboxylic acid derivative containing thiazole ring and pharmaceutical use thereof |
CN2009801558737A CN102300853A (zh) | 2008-12-01 | 2009-12-01 | 含有噻唑环的羧酸衍生物及其药学用途 |
CA2744985A CA2744985C (en) | 2008-12-01 | 2009-12-01 | Carboxylic acid derivative containing thiazole ring useful for the prevention or treatment of hyperlipidemia |
JP2010541324A JP5357894B2 (ja) | 2008-12-01 | 2009-12-01 | チアゾール環を含むカルボン酸誘導体およびその医薬用途 |
US13/132,292 US8497382B2 (en) | 2008-12-01 | 2009-12-01 | Carboxylic acid derivative containing thiazole ring and pharmaceutical use thereof |
EP09830399.3A EP2380884B1 (en) | 2008-12-01 | 2009-12-01 | Carboxylic acid derivative containing thiazole ring and pharmaceutical use thereof |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2008-306803 | 2008-12-01 | ||
JP2008306803 | 2008-12-01 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2010064633A1 true WO2010064633A1 (ja) | 2010-06-10 |
Family
ID=42233281
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2009/070185 WO2010064633A1 (ja) | 2008-12-01 | 2009-12-01 | チアゾール環を含むカルボン酸誘導体およびその医薬用途 |
Country Status (9)
Country | Link |
---|---|
US (1) | US8497382B2 (ja) |
EP (1) | EP2380884B1 (ja) |
JP (1) | JP5357894B2 (ja) |
KR (1) | KR101290868B1 (ja) |
CN (1) | CN102300853A (ja) |
AU (1) | AU2009323367B2 (ja) |
CA (1) | CA2744985C (ja) |
TW (1) | TW201022221A (ja) |
WO (1) | WO2010064633A1 (ja) |
Citations (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1996015784A2 (de) | 1994-11-09 | 1996-05-30 | Boehringer Mannheim Gmbh | 2,2-dichloralkancarbonsäuren, verfahren zu ihrer herstellung diese enthaltende arzneimittel, und ihre verwendung zur behandlung der insulinresistenz |
WO1996023756A1 (fr) | 1995-02-03 | 1996-08-08 | Kaneka Corporation | PROCEDES DE PRODUCTION D'α-HALOCETONES, D'α-HALOHYDRINES ET D'EPOXYDES |
WO2000023407A2 (en) | 1998-10-16 | 2000-04-27 | Glaxo Group Limited | Ureido-thiobutyric acid derivatives as ppar-agonists |
WO2000075103A1 (fr) | 1999-06-09 | 2000-12-14 | Kyorin Pharmaceutical Co., Ltd. | DERIVES D'ACIDE PHENYLPROPIONIQUE SUBSTITUES COMME AGONISTES DU RECEPTEUR HUMAIN ACTIVE DE LA PROLIFERATION DES PEROXYSOMES (PPAR) $g(a) |
WO2001090087A1 (fr) | 2000-05-26 | 2001-11-29 | Nippon Shinyaku Co., Ltd. | Composes heterocycliques |
WO2002028821A2 (de) | 2000-10-05 | 2002-04-11 | Bayer Aktiengesellschaft | Propionsäurederivate mit ppar-alpha aktivierenden eigenschaften. |
WO2002038553A2 (en) | 2000-11-10 | 2002-05-16 | Eli Lilly And Company | Triazole derivatives and their use as peroxisome proliferator activated receptor alpha agonists |
WO2002096894A1 (en) | 2001-05-31 | 2002-12-05 | Glaxo Group Limited | Thiazole or oxazole derivatives which are useful in the treatment of cardiovascular and related diseases |
WO2006049232A1 (ja) | 2004-11-04 | 2006-05-11 | Mitsubishi Pharma Corporation | チアゾール環を含むカルボン酸誘導体およびその医薬用途 |
WO2007126043A1 (ja) * | 2006-04-27 | 2007-11-08 | Mitsubishi Tanabe Pharma Corporation | チアゾール環を含むカルボン酸誘導体の医薬用途 |
JP2008527021A (ja) * | 2005-01-19 | 2008-07-24 | アダムド エスピー.ゼット オー.オー. | 新規な3−フェニルプロピオン酸誘導体およびそのPPARγ受容体リガンドとしての使用 |
JP2008306803A (ja) | 2007-06-06 | 2008-12-18 | Denso Corp | 車両用制御装置 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP4790969B2 (ja) | 2000-08-11 | 2011-10-12 | 日本ケミファ株式会社 | ペルオキシソーム増殖剤応答性受容体δの活性化剤 |
GB0113231D0 (en) * | 2001-05-31 | 2001-07-25 | Glaxo Group Ltd | Chemical compounds |
EP1424330B1 (en) * | 2001-08-10 | 2011-09-28 | Nippon Chemiphar Co., Ltd. | Activator for peroxisome proliferator-responsive receptor delta |
EP1964575B1 (en) * | 2005-11-28 | 2015-09-23 | Senju Pharmaceutical Co., Ltd. | Pharmaceutical comprising ppar agonist |
-
2009
- 2009-12-01 EP EP09830399.3A patent/EP2380884B1/en not_active Not-in-force
- 2009-12-01 CN CN2009801558737A patent/CN102300853A/zh active Pending
- 2009-12-01 JP JP2010541324A patent/JP5357894B2/ja not_active Expired - Fee Related
- 2009-12-01 TW TW098140943A patent/TW201022221A/zh unknown
- 2009-12-01 WO PCT/JP2009/070185 patent/WO2010064633A1/ja active Application Filing
- 2009-12-01 AU AU2009323367A patent/AU2009323367B2/en not_active Ceased
- 2009-12-01 US US13/132,292 patent/US8497382B2/en not_active Expired - Fee Related
- 2009-12-01 KR KR1020117015086A patent/KR101290868B1/ko not_active IP Right Cessation
- 2009-12-01 CA CA2744985A patent/CA2744985C/en not_active Expired - Fee Related
Patent Citations (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1996015784A2 (de) | 1994-11-09 | 1996-05-30 | Boehringer Mannheim Gmbh | 2,2-dichloralkancarbonsäuren, verfahren zu ihrer herstellung diese enthaltende arzneimittel, und ihre verwendung zur behandlung der insulinresistenz |
WO1996023756A1 (fr) | 1995-02-03 | 1996-08-08 | Kaneka Corporation | PROCEDES DE PRODUCTION D'α-HALOCETONES, D'α-HALOHYDRINES ET D'EPOXYDES |
JP2002527496A (ja) * | 1998-10-16 | 2002-08-27 | グラクソ グループ リミテッド | 化学化合物 |
WO2000023407A2 (en) | 1998-10-16 | 2000-04-27 | Glaxo Group Limited | Ureido-thiobutyric acid derivatives as ppar-agonists |
WO2000075103A1 (fr) | 1999-06-09 | 2000-12-14 | Kyorin Pharmaceutical Co., Ltd. | DERIVES D'ACIDE PHENYLPROPIONIQUE SUBSTITUES COMME AGONISTES DU RECEPTEUR HUMAIN ACTIVE DE LA PROLIFERATION DES PEROXYSOMES (PPAR) $g(a) |
WO2001090087A1 (fr) | 2000-05-26 | 2001-11-29 | Nippon Shinyaku Co., Ltd. | Composes heterocycliques |
WO2002028821A2 (de) | 2000-10-05 | 2002-04-11 | Bayer Aktiengesellschaft | Propionsäurederivate mit ppar-alpha aktivierenden eigenschaften. |
WO2002038553A2 (en) | 2000-11-10 | 2002-05-16 | Eli Lilly And Company | Triazole derivatives and their use as peroxisome proliferator activated receptor alpha agonists |
WO2002096894A1 (en) | 2001-05-31 | 2002-12-05 | Glaxo Group Limited | Thiazole or oxazole derivatives which are useful in the treatment of cardiovascular and related diseases |
WO2006049232A1 (ja) | 2004-11-04 | 2006-05-11 | Mitsubishi Pharma Corporation | チアゾール環を含むカルボン酸誘導体およびその医薬用途 |
JP2008527021A (ja) * | 2005-01-19 | 2008-07-24 | アダムド エスピー.ゼット オー.オー. | 新規な3−フェニルプロピオン酸誘導体およびそのPPARγ受容体リガンドとしての使用 |
WO2007126043A1 (ja) * | 2006-04-27 | 2007-11-08 | Mitsubishi Tanabe Pharma Corporation | チアゾール環を含むカルボン酸誘導体の医薬用途 |
JP2008306803A (ja) | 2007-06-06 | 2008-12-18 | Denso Corp | 車両用制御装置 |
Non-Patent Citations (13)
Title |
---|
"Jikken Kagaku Kouza 19 organic compound synthesis VII", pages: 65 - 170 |
"Jikken Kagaku Kouza 26 organic synthesis VIII", pages: 23 - 68 |
AM. J. PHYSIOL., vol. 283, 2002, pages H949 |
BIOORG. MED. CHEM. LETT., vol. 11, 2001, pages 1225 |
BIOORG. MED. CHEM. LETT., vol. 12, 2002, pages 333 |
DIABETES, vol. 47, 1998, pages 1841 - 1847 |
J. CHEM. SOC. CHEM. COMMUN., 1994, pages 969 |
J. MED. CHEM., vol. 42, 1999, pages 3785 |
J. MED. CHEM., vol. 42, 1999, pages 3785 - 3788 |
J. MED. CHEM., vol. 46, 2003, pages 5121 |
J. ORG. CHEM., vol. 20, 1955, pages 38 |
See also references of EP2380884A4 |
TETRAHEDRON LETT., vol. 42, 2001, pages 5887 |
Also Published As
Publication number | Publication date |
---|---|
AU2009323367B2 (en) | 2013-05-23 |
TW201022221A (en) | 2010-06-16 |
JP5357894B2 (ja) | 2013-12-04 |
KR20110088597A (ko) | 2011-08-03 |
EP2380884A1 (en) | 2011-10-26 |
CN102300853A (zh) | 2011-12-28 |
CA2744985C (en) | 2014-05-06 |
US8497382B2 (en) | 2013-07-30 |
EP2380884B1 (en) | 2014-02-12 |
CA2744985A1 (en) | 2010-06-10 |
JPWO2010064633A1 (ja) | 2012-05-10 |
KR101290868B1 (ko) | 2013-07-29 |
EP2380884A4 (en) | 2012-06-06 |
US20110237630A1 (en) | 2011-09-29 |
AU2009323367A1 (en) | 2011-07-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5243696B2 (ja) | ベンゼン誘導体 | |
JP6049791B2 (ja) | ペルオキシソーム増殖剤活性化受容体δの活性化剤 | |
JP3997491B2 (ja) | カルバゾール誘導体、その溶媒和物、又は薬学的に許容されるその塩 | |
JP5225076B2 (ja) | チアゾール環を含むカルボン酸誘導体の医薬用途 | |
JP6215832B2 (ja) | アミノピリミジンキナーゼ阻害剤 | |
EP2007726B1 (en) | Benzamide and heteroarene derivatives as cetp inhibitors | |
WO2008016175A1 (fr) | Agent activant de récepteur activé par les proliférateurs des peroxysomes | |
WO2006049232A1 (ja) | チアゾール環を含むカルボン酸誘導体およびその医薬用途 | |
WO2016031987A1 (ja) | オートタキシン阻害活性を有するピリミジノン誘導体 | |
WO2018005807A1 (en) | 1 h-pyrazol-1 -yl-thiazoles as inhibitors of lactate dehydrogenase and methods of use thereof | |
US20170158704A1 (en) | Pyrimidinone derivative having autotaxin-inhibitory activity | |
WO2002051820A1 (fr) | Composes derives de dihydronaphtalene et medicaments utilisant ces composes comme ingredient actif | |
JP5357894B2 (ja) | チアゾール環を含むカルボン酸誘導体およびその医薬用途 | |
MX2015002624A (es) | Nuevas tiofenilamidas no anuladas como inhibidores de las proteinas de union a acido graso (fabp) 4 y/o 5. | |
JP2002212179A (ja) | 新規アニリド誘導体又はその塩及びこれを含有する医薬 | |
AU2020320034A1 (en) | Inhibitors of human ATGL | |
WO2004067495A1 (fr) | Composes d'alanine, leur procede de preparation et leur utilisation | |
JP3836521B2 (ja) | 2,4−チアゾリジンジオン誘導体、その製造法およびそれを含んでなる医薬組成物 | |
JP2004161634A (ja) | 新規ピラゾール化合物 | |
JP2013006769A (ja) | ペルオキシソーム増殖剤活性化受容体の活性化剤 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 200980155873.7 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 09830399 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2010541324 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2744985 Country of ref document: CA Ref document number: 12011501043 Country of ref document: PH |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 13132292 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2009830399 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2009323367 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 4550/CHENP/2011 Country of ref document: IN |
|
ENP | Entry into the national phase |
Ref document number: 20117015086 Country of ref document: KR Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 2009323367 Country of ref document: AU Date of ref document: 20091201 Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 13132292 Country of ref document: US |